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Enterovirus 71 (EV71), belonging to Picornaviridae family, is a major cause of Hand-Foot-and-
Mouth Disease (HFMD) in young children with worldwide distribution. Large outbreaks of the 
disease with cases of neurological complications and fatalities have occurred throughout the 
Asia-Pacific region including Singapore. HFMD is considered as an important emerging public 
health threat particularly due to its total economic burden. 
Presently, there is no licensed vaccine to protect children against EV71 infection; only 
supportive treatment is provided. Although vaccine development studies against EV71 are 
reported, there is still need for further development of safe vaccines that can confer broad 
immunogenicity and protection against EV71 infection. The main immunogenic capsid protein 
of EV71, VP1, has been the focus of EV71 subunit vaccine development by many researchers.  
The aim of this project is to investigate the feasibility of VP1 vaccine antigen production in two 
novel expression systems, i.e. Chinese hamster ovary (CHO) cells and Blastocystis sp. This may 
lead to development of new vaccine candidates against EV71, namely CHO-derived VP1 as 
subunit vaccine for parenteral immunization, and Blastocystis-derived VP1 as live recombinant 
vaccine for oral immunization.  
A set of pcDNA3.1 mammalian expression vectors containing GFP tag and myc/His tag were 
constructed by cloning the VP1 antigen fused to CHO adiponectin and Blastocystis legumain 
signal peptides. VP1 expression in CHO cells was analyzed by Western blotting. GFP reporter 
expression in Blastocystis was assessed by confocal microscopy and flow cytometric analyses.  
In this project, His-tagged VP1 production in CHO cells was successfully achieved. However, 
further protein over-expression strategies including the creation of stable recombinant CHO cell 
lines and secretion engineering are needed to enhance and scale up the VP1 production yield. 
vii 
 
These strategies will facilitate the subsequent purification of VP1 by Immobilized Metal Affinity 
Chromatography (IMAC) for end-use CHO-derived VP1 vaccine. 
Although electroporation conditions were optimized empirically for Blastocystis cells to attain 
higher cell viability, multiple attempts to establish Blastocystis cells expressing the constructed 
mammalian-based GFP expression vectors resulted in relatively low GFP expression. 
Considering the numerous unknowns and drawbacks for establishment of heterologous gene 
expression in Blastocystis, further stepwise investigations are required to characterize an efficient 
transfection method with maximum DNA uptake efficiency and cell viability. Furthermore, 
bioinformatics analyses of Blastocystis promoters can facilitate design and construction of 
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1. CHAPTER 1: LITERATURE REVIEW 
 
1.1 Hand, foot and Mouth Disease: A threat for children 
 
 
1.1.1 Hand, foot and mouth Disease (HFMD)  
 
Hand, foot and mouth disease (HFMD) is a common viral illness that mostly affects infants and 
children. The virus can be transmitted through faeco-oral route. HFMD is characterized by 
clinical manifestations including fever, sore throat, and blisters in the mouth, on the tongue 
and/or distal extremities such as on the palm of hands, soles of feet or buttocks. These symptoms 
are usually mild and self-limiting. However, HFMD may progress to serious cardiac or 
neurological disorders such as myocarditis, aseptic meningitis, acute poliomyelitis-like acute 
flaccid paralysis, and fatal encephalitis (Ooi et al. 2010; Sabanathan et al. 2014).  
 
 
1.1.2 Prevalence of HFMD 
 
HFMD has a worldwide distribution, with outbreaks reported all over the world, including 
countries such as Hungary, Bulgaria, Finland, Australia, Japan, Hong Kong, Taiwan, and  
China (Lin et al. 2003). However, there has been increasing reports of the disease throughout the 
Asia-Pacific region since 1997 (Yip et al. 2013) and has become a pressing global public health 
problem. A large outbreak of HFMD in Taiwan in 1998 affected more than 100,000 children, 
caused over 400 hospitalizations, and resulted in 78 deaths due to pulmonary edema and 
neurogenic shock (Lin, Twu et al. 2003).  
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HFMD is endemic in Singapore. Annual outbreaks have been reported in Singapore since 2000, 
numbering more than 5,000 HFMD cases every year (MOH, 2014). Singapore experienced one 
of its largest outbreaks of HFMD in 2008, resulting in 29,686 cases of HFMD, including four 
cases of encephalitis and one fatality (Wu et al. 2010b). The incidence of HFMD in Singapore 
has risen from 346.4 cases per 100,000 population in 2009 to 698.8 cases per 100,000 population 
in 2012. The accumulation of children susceptible to CV-A6 infection could have led to the 
largest HFMD epidemic in the last decade in 2012 (Ang et al. 2015). 
 
1.1.3 Significance of HFMD 
 
A small proportion of children with HFMD infection may experience severe neurological 
complications that are potentially fatal. These complications are not the main concern at both 
national and local levels. However, socio-economic burden imposed by HFMD outbreaks has 
already received considerable attention from Singapore, Ministry of Health (MOH). 
Most of the HFMD outbreaks in Singapore occurred in childcare centers where preschool 
children below 5 years of age congregated. This indicated that young children aged 1–5 years 
were most susceptible to the three enteroviruses (CA-6, CA-16 and EV71) (Ang et al. 2015).  
To curb the HFMD transmission, MOH maintained rigorous control measures for the disease 
including widespread public education, and mandatory closures of preschools and childcare 
centers with significant numbers of HFMD cases and prolonged transmission of the disease (Lim 
et al. 2015). This would lead to significant impact on Singapore’s economy considering the 
closures will cause great inconvenience to parents, having to take childcare leave leading to a 
loss in productivity as well as to incur the cost of treatment.   
 3 
 
1.1.4 Etiologic agent of HFMD 
 
The common causative agents responsible for large outbreaks of HFMD worldwide are 
enterovirus 71 (EV71) and coxsackievirus A16 (CA16). The clinical manifestations of HFMD 
caused by EV71 and CA16 are indistinguishable, but EV71 infection can lead to severe 
neurological disease and even death (Singh et al. 2002a; Zhang et al. 2015). 
The predominant circulating enteroviruses associated with HFMD epidemics in Singapore 
alternated between CA16 and EV71 during the period 2005–2009. CA16 and CA6 were 




1.1.5 Current treatment and management of HFMD 
 
There is no specific therapy available for HFMD at present. Only supportive care is provided as 
the mainstay of treatment for HMFD. Currently, the only recommended control measures for 
HFMD are through hygiene and social distancing between infected and susceptible individuals to 
curb the spread of virus. 
Personal hygiene and good sanitation, including frequent hand washing has proven particularly 
effective in preventing disease transmission. In addition, public health measures such as 
mandatory closures of affected childcare facilities and schools during HFMD outbreaks in 
Singapore have proven effective in limiting virus transmission in crowded settings (Ruan et al. 
2011). However, since HFMD is endemic in Singapore and other parts of the world, it is crucial 





1.2 Enterovirus 71 (EV71) 
 
 
1.2.1 Phylogeny and Classification 
 
EV71 belongs to the Enterovirus genus of the Picornaviridae family. The Picornaviridae are 
presently divided into nine genera, three of which (Hepatoviruses, Rhinoviruses, and 
Enteroviruses) are human pathogens (Song et al. 2014). Enteroviruses, as their name indicates, 
replicate mainly in the intestinal tract as the initial site, and then spread into the bloodstream and 
into organ systems. 
Enteroviruses include the echoviruses, polioviruses, coxsackie A and B viruses and other 
enteroviruses types 68 to 71 (EV68-EV71). Enteroviruses are phylogenetically classified into 
four species (A, B, C, and D) (Lee et al. 2012). 
 
 
1.2.2 Genome structure and properties  
 
EV71 is a small (~30 nm in diameter), non-enveloped virus with a single-stranded, positive-
sense RNA genome (~7.4 kb) encapsulated in an icosahedral capsid (Lyu et al. 2015). 
EV71 possesses a linear ssRNA (+) genome of approximately 7500 nucleotides. Viral genomic 
RNA has a viral protein (VPg) at its 5′ end instead of a methylated nucleotide cap structure 
(Figure 1). After entry to the host cells, the viral genome, which comprises a single open reading 
frame (ORF) and lacks a 5′cap is translated in a cap-independent manner into a single 
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polyprotein by the aid of an internal ribosome entry site (IRES) in its 5′ untranslated region 
(5′UTR). The resulted polyprotein divides into three regions P1, P2, and P3. The P1 region will 
be processed to four structural polypeptides (VP1, VP2, VP3, and VP4). The P2 and P3 regions 
will be subsequently processed to the nonstructural proteins associated with virus replication and 
virulence (Nicklin et al. 1987; Hu et al. 2003).  
The four structural proteins of EV71, VP1-VP4, are vital in forming the characteristic 
pentameric icosahedral capsid of the virus (Lal et al. 2006). Known to be one of the most stable 
viruses because of its capsid structure, EV71 can withstand temperature fluctuation and survive 
after sewage treatment (Rajtar et al. 2008). Furthermore, EV71 is able to withstand acidic pH 
such as the environment of the gastrointestinal tract (Lal, Kumar et al. 2006).  
 
Figure 1. Schematic representation of EV71 genome structure. (Adapted from (Shih et al. 
2011)). 
 
1.2.3 VP1 protein  
 
EV71 capsid is composed of four structural proteins, VP1, VP2, VP3 and VP4. While VP4 is 
embedded in the virus capsid, other three capsid proteins are exposed to the virus surface (Figure 
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2). VP1 is known as the main immunogenic capsid protein of EV71 and is widely considered as 
the candidate antigen for vaccine development against EV71 (Wang et al. 2013). Moreover, VP1 
plays the main role in self-association and development of the icosahedral capsid which leads to 
the infectivity and stability of the virions to withstand the harsh environment of the 
gastrointestinal tract (Lal, Kumar et al. 2006) as well as the attachment of EV71 virus to target 
cells. Antibodies against VP1 are critical for virus neutralization (Yeo & Chow 2007). 
 
 
Figure 2. Cartoon representation of EV71 capsid proteins. The capsid consists of 4 polypeptides, 
VP1, VP2, VP3 and VP4 which are surrounding the naked RNA genome. VP4 is located on the 






EV71 has been isolated from stool specimens and respiratory secretions of children infected with 
EV71 indicating that the virus transmission can occur through both fecal-oral (Yang et al. 2009a) 
and respiratory (Hamaguchi et al. 2008) routes. Therefore, direct person-to-person contact with 
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discharge from the throat, nose, saliva, and blisters or stools of infected persons can transmit the 
virus [Ooi et al. 2010]. EV71 is typically shed during the first week of the illness, and sometimes 
can continue for up to 11 weeks post-infection (Lui et al. 2007). 
Various studies have shown that initial replication of EV71 begins in the intestinal tract. The 
virus then passes through the gut barrier and infects the muscle cells where persistent virus 
replication occurs. The virus can spread into bloodstream and further progress to the central 
nervous system (CNS) in more severe cases (Lui et al. 2013).  
 
 
1.2.5 Epidemiology of EV71 infection 
 
Although EV71 infection is often asymptomatic, it can present symptoms ranging from HFMD, 
meningitis, encephalitis, myocarditis, and polio-like disease. EV71 was initially isolated and 
characterized in fecal matter of a baby with encephalitis in California in 1969 (Lin et al. 2002). 
Since then EV71 was recognized in sporadic cases of outbreaks in different parts of the world, 
including Hungary (Nagy et al. 1982), Australia (Gilbert et al. 1988), Hong Kong (Samuda et al. 
1987), Taiwan (Ho et al. 1999), Japan (Fujimoto et al. 2002) and China (Yang et al. 2009b).  
In Asia, EV71 has been causing broad epidemics of HFMD and periodic neuroinfection, 
particularly in the last 15 years. Since 2008, consistent epidemics of EV71 infection with over a 
million cases have been registered in China. In Europe, extensive outbreaks of polio-like disease 




Recently, EV71 has attracted major attention in Singapore due to large outbreaks occurred in 
2000 and 2008 (Lal, Kumar et al. 2006; Wu, Yeo et al. 2010b). It is not known why the 
virulence and communicability of EV71 diseases fluctuate. It may be associated with diminished 
population immunity or mutations affecting the virus’ virulence. Thus, EV71 is viewed a critical 
emerging public health threat (Chan et al. 2000; Cheng et al. 2013). 
 
 
1.2.6 Diagnosis, treatment and prevention 
 
Numerous diagnostic tests have been developed for the detection of EV71 infection, depending 
on the manifestations of the disease. Performing PCR on throat swabs and swabs from at least 
two vesicles or from the rectum of patients with no vesicles was found as the most efficient 
approach for diagnosis of EV71 infection. In cases that have CNS involvement, lumbar 
punctures are essential for diagnosis (Ooi, Wong et al. 2010). 
Presently, there is no established antiviral or safe vaccine available for EV71 infection and 
treatment remains symptomatic to provide relief from fever and pain (Tan et al. 2012). 
 
 
1.3 Vaccine development against EV71 
 
The success of live-attenuated (Sabin) and inactivated (Salk) polio vaccines in preventing 
poliomyelitis demonstrates the potential for forestalling EV71 infection by vaccination (Lee & 
Chang 2010).  
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Although extensive studies have been reported for vaccine development against EV71, there is 
still need for development of a suitable vaccine which is safe and able to elicit protective 
responses against EV71 (Chong et al. 2012). Previous vaccine candidates have their own 
drawbacks such as inefficiency and safety issues for human application. An overview of the 




1.3.1 Inactivated virus vaccines  
 
Inactivated virus vaccines, as routine immunizations, for example, inactivated influenza vaccine 
(Nichol 2003) and inactivated hepatitis A vaccine (Clarke et al. 2001) , have been effectively 
utilized in the human.  
Seroepidemiologic studies have demonstrated that the preexisting neutralizing antibody to EV71 
is protective against the serious outcomes of disease (Ho, Chen et al. 1999; Chang et al. 2002). It 
has been shown that passive transfer of serum from adult mice immunized with formalin-
inactivated and heat inactivated virus vaccine could give protection against EV71 challenge in 
neonatal mice (Yu et al. 2000; Wu et al. 2001); in the interim, maternal immunization with 
inactivated EV71 vaccine had the capacity to prolong the survival of suckling mice after EV71 
lethal challenge. These outcomes demonstrate the value of the inactivated virus vaccine for the 
successful control of EV71. On the other hand, the conservation of the three dimensional 
structure is critical in order to induce a strong immune response. In this manner, for the heat-
inactivated virus, a much higher dose of viral antigen and adjuvant are obliged to achieve a 
satisfactory level of immunogenicity and protection (Zhang et al. 2010). 
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A potential live-attenuated EV71 vaccine candidate created by the Shimizu’s group in Japan 
(Arita et al. 2007) had been indicated to elicit a wide range of neutralizing antibody responses 
against diverse genotypes of EV71 in cynomolgus monkeys, however mild neurological 
manifestations were observed. The worry over potential inversion of live-attenuated vaccine to 
virulence (Diamanti et al. 1998; Chan et al. 2001) has made chemically-inactivated virion-based 
vaccines a more alluring choice for EV71 vaccine improvement. Formalin inactivated EV71 
virion (EV71inac) was found to prompt superior immune responses compared with the other 
vaccine candidates. Interestingly, antisera generated from either rabbits or non-human primate 
macaques vaccinated with the same amount (2 μg) of EV71inac formulated with alum greatly 
cross-neutralized diverse EV71 subgenotypes and weakly cross-neutralized CVA16, with average 
titers of 1/6,400 and 1/32, respectively.  
EV71inac vaccine candidates were exceptionally immunogenic and could evoke cross-genotype 
neutralizing antibody responses in mice and non-human primate models. Taking into account 
current data, the best formulation for creating a stable and cost-effective HFMD vaccine is a mix 
of EV71inac and CAV16inac (Chong, Hsieh et al. 2012). 
Since HFMD poses a major threat to the preschool children in Asian developing countries, an 
ideal EV71 vaccine ought to be inexpensive, safe, and easy to administer; these features can also 
impact parents to accept the vaccine for their children. As specified above, inactivated EV71 
virions are the most encouraging EV71 vaccines and could be licensed by regulatory agencies 
sooner than whatever other EV71 vaccine candidates. 
A clinical trial of formalin-inactivated EV71 virion vaccine combined with alum was tested 
during the 1975 Bulgarian epidemic, however the detailed outcomes of the trial were not 
published (Chumakov et al. 1979). Inactivated EV71 virion vaccines based on various EV71 
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strains utilizing diverse manufacturing technologies have been created and completed human 
phase 1 clinical trials in China, Taiwan and Singapore (Chong, Hsieh et al. 2012). 
Thus far, several clinical trials have been completed on the inactivated EV71 whole-virus 
vaccines from various manufacturers in China, Taiwan and Singapore (Chong, Hsieh et al. 
2012). Published clinical trial results have demonstrated that the inactivated EV71 whole-virus 
vaccines have good safety and immunogenicity in infants and children with over 90% of EV71-
associated HFMD and 80% of EV71-associated diseases (Liang & Wang 2014). The results of 







1.3.2 Peptide based vaccines 
 
Foo et al. (2007) showed that a synthetic peptide (SP70) containing residues 211–215 of VP1 
evoked virus-neutralizing antibody response (1/32 titer) and protected infant mice against lethal 
EV71 challenges by passive immunization. Multiple synthetic peptides with linear 
immunodominant neutralization epitopes have been produced and tested in both BALB/c and 
C56BL/6 mice at various doses (10 to 100 μg) of either without or with alum, or complete 
Freund’s adjuvant (CFA), or incomplete Freund’s adjuvant (IFA) (Foo et al. 2007a; Foo et al. 
2007b; Liu et al. 2011a). Synthetic peptides combined with CFA/IFA could elicit antibody 
responses as determined by the peptide-ELISA and western blot tests (Chong, Hsieh et al. 2012). 
However, synthetic peptide based vaccines are intrinsically ineffective immunologically and 
need to be formulated in a strong adjuvant such as CFA that is not acceptable by the regulatory 
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agencies. In this manner, much more work is expected to create efficacious synthetic peptide-
based EV71 vaccines acceptable from the regulatory and commercial point of view (Chong, 
Hsieh et al. 2012). 
 
 
1.3.3 Recombinant subunit vaccines 
 
Recombinant DNA technology, in which just the target subunit antigen is delivered and less 
adverse effects are brought on, is hypothetically the innovative decision for vaccine production 
and may be applicable in most viral infections. The isolated viral surface proteins possess 
neutralizing epitopes; one such successful case is hepatitis B virus vaccine (Margolis 1993). 
Since the VP1, VP2 and VP3 structural proteins are located on the EV71 viral surface, they 
could serve as focuses for EV71 subunit vaccine development. To compare the immune 
responses they stimulate in mice, rVP1, rVP2 and rVP3 were produced, purified and mixed with 
or without alum.  
Mouse antisera were found to recognize the individual proteins on western blots, yet none of 
them could neutralize EV71 virus in vitro. Notwithstanding, in the presence of CFA/IFA, 
recombinant VP1 was the main subunit capable of eliciting antibody responses with EV71 
neutralization titers of 1/128 (Wu, Lin et al. 2001). 
It was also found by Chiu et al. (Chiu et al. 2006) that rVP1 expressed in Salmonella 
typhimurium and purified for vaccine in combination with CFA/IFA induced EV71-specific 
neutralizing antibody responses and protected sucking mice in challenge study.  
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Low levels of EV71-specific neutralizing antibodies (1/32 titer) could be created by oral 
inoculation of mice utilizing transgenic tomatoes expressing the VP1 protein (Chen et al. 2006).  
Although edible vaccines had been poised to be the next wave of human vaccines for developing 
countries, regulatory issues as well as its poor immunogenicity will most likely be the major 
obstacles for them to be licensed and utilized in humans. This is especially so since their stability 
will not last more than two months (Chong, Hsieh et al. 2012). 
 
 
1.3.4 DNA vaccines  
 
DNA vaccines have extraordinary potential for vaccine development because their gene products 
are expressed inside the cells similar to a natural viral infection scenario and in this way could 
induce both humoral and cellular immunity. 
Mouse immunogenicity investigations of EV71 DNA vaccine harboring the VP1 gene have been 
reported by Wu et al., (Wu, Lin et al. 2001) and Tung et al (Tung et al. 2007). VP1-based DNA 
vaccine candidates could elicit low levels of mouse neutralizing antibody responses at high doses 
(100 μg of DNA plasmid). As of now, DNA vaccine has not possessed the capacity to elicit 
strong antibody responses in humans. No human DNA vaccine has been so far licensed, and 
critical changes are fundamental before a genetic EV71 vaccine becomes a significant alternative 






1.3.5 VLP-based vaccines  
 
Chung et al., had reported that 10 μg of EV71 VLPs mixed with CFA could result in virus 
neutralizing antibody responses with a titer of 1/512 in mice and protect infant mice against 
lethal EV71 challenges by passive immunization. In both rabbit and nonhuman primate 
immunogenicity studies, a high dosage (> 100 μg) of VLP-EV71 in combination with alum 
could elicit virus neutralizing antibody responses (Chung et al. 2010). However, the time needed 
for recombinant baculovirus VLP-EV71 constructs and insect cells to be GMP certified, and the 
expense of VLP-EV71 vaccine production (> 100 μg/ dose) would prevent a VLP-EV71 vaccine 
candidate to enter phase 1 clinical trials sooner rather than later (Chong, Hsieh et al. 2012). 
 
 
1.3.6 Recombinant oral vaccines  
 
To date most of the studied EV71 vaccine candidates are administered parenterally which is 
limited to stimulating systemic immunity, whereas a mucosal vaccine would be able to provide 
both systemic and mucosal immunity (Ogra et al. 2001). Therefore, oral vaccination seems to be 
an appealing alternative to parenteral immunization (Premanand et al. 2013).  
In recent years, mucosal stimulation and antigen delivery strategies via live carriers for inducing 
immune response against EV71 has been reported in few studies. Salmonella expressing VP1 
protein was used for oral immunization of mice against EV71 and could induce both humoral 
and cellular immune responses against EV71. However, mucosal responses were not studied in 
this case (Chiu, Chu et al. 2006). VP1 antigen was successfully displayed on the surface of food-
 15 
 
grade Lactococcus lactis which could be a potential live vehicle for the delivery of VP1 to the 
gut (Raha et al. 2005; Varma et al. 2013). Another candidate was Bifidobacterium longum, 
which was shown to be an effective oral vaccine against EV71 infection (Yu et al. 2013). 
 
 
1.4 Commonly used recombinant expression systems 
 
The development of genetic engineering and cloning have enabled researchers to use a living 
organism’s protein expression system for production and isolation of heterologous (recombinant) 
proteins (Makino et al. 2011). Expression systems are routinely used for research purposes as 
well as for production of biopharmaceuticals such as antibody, enzyme or vaccine. The 
commonly used protein expression systems are bacteria, yeast, insect and mammalian systems. 
Table 1 summarizes their advantages, disadvantages and potential applications. 
 
Table 1. Key features of some commonly used expression systems 
Expression 
system 







Potentially very high expression 
levels; low cost; simple culture 
conditions; rapid growth; scalable; 
simple transformation protocols; 
Many parameters can be altered to 
optimize expression 
Disadvantages 
Inefficient disulfide bond formation; 
poor folding of proteins in the 
cytoplasm; inclusion body formation; 
in vitro refolding protocols 




Purified protein (structure, 
enzymology, drug discovery); 
Protein therapeutics 





Good expression levels; Choice of 
secreted or cellular expression; Low 









cost; simple culture conditions; 
Scalable; Able to perform most 
eukaryotic post-translational 
modifications; efficient protein 
folding; Endotoxin-free 
Disadvantages 
Likely lower expression than Pichia 
pastoris; Secretion likely lower than 
Pichia pastoris; Glycosylation still 
different to mammalian cells; 
Tendency to hyperglycosylate 









High expression levels; Low cost; 
Simple culture conditions; Relatively 
rapid growth; Scalable; Choice of 
secreted or intracellular expression; 
Protein secretion efficient and allows 
simple purification; Extensive post-
translational modification of proteins; 
Efficient protein folding; N-
glycosylation more like higher 
eukaryotes than with Saccharomyces 
cerevisiae; Endotoxin-free 
Disadvantages 
Use of methanol as inducer is a safety 
(fire) hazard at scale; Glycosylation 
still different to mammalian cells 
 
Purified protein (structure, 
enzymology, drug discovery) 






Good expression levels (esp. for 
intracellular proteins); Relatively 
rapid growth; Efficient protein 
folding; Moderately scalable; 
Extensive post-translational 
modification of proteins; 
Glycosylation more like mammalian 
cells; Relatively easy deglycosylate 




Expensive culture media; Large 
volumes of virus needed on scale-up; 
Inefficient processing of pro-peptides 
in secretory pathway; Glycosylation 
still different to mammalian cells; 
Viral infection leads to cell lysis and 
potential degradation of expressed 
proteins 
Purified protein (structure, 







Good expression levels; Moderately 
scalable; Suspension-adapted cells 
facilitate scale-up; Efficient protein 
folding; Good for secreted proteins; 
All post-translational modifications; 
Endotoxin-free 
Disadvantages 
Expensive culture media; Complex 
growth requirements 
 
Purified protein (structure, 
enzymology, drug discovery); 
Protein therapeutics; Cell-
based studies 
(Almo & Love 2014) 




1.5 Mammalian expression system 
 
Mammalian expression system is the common method for production of biopharmaceutical 
proteins and its utilization is growing in popularity among academic laboratories (Butler 2005). 
Mammalian cell hosts are more probable than lower eukaryotic cell hosts to express, 
appropriately fold, and result in native-like post-translational modifications of mammalian 
proteins. Moreover, stable mammalian cell lines can provide a consistent and reliable source of 
protein expression. They can be stored under cryogenic conditions for a long time, retrieved, and 
cultured. 
While mammalian cells are widely used for protein expression in the pharmaceutical industry, 
production of proteins in academic labs using mammalian cells have been relatively slow due to 






1.5.1 Chinese Hamster Ovary (CHO) based vaccine 
 
Several rodent- or human-derived cells such as BHK and HeLa have been used for heterologous 
protein expression. However Chinese hamster ovary (CHO) cells served as the favored 
mammalian cell line for the production of recombinant therapeutic proteins. Nearly 70% of 
protein therapeutics are produced in CHO. The popularity of CHO cells can be credited to the 
following reasons: (1) CHO cells are capable of adjusting and growing in suspension culture 
which is perfect for large scale culture in the industry; (2) CHO cells have been shown as safe 
hosts; thus obtaining approval to market the therapeutic proteins from regulatory agencies like 
the FDA seems easier (Kim et al. 2012); (3) CHO cells can grow in serum-free and chemically 
defined media which guarantees reproducibility between various batches of cell culture; (4) CHO 
cells permit post translational modifications to recombinant proteins leading to more 
compatibility and bioactivity in humans (Wurm & Hacker 2011).  
One successful example of viral vaccine developed in CHO cells is hepatitis B vaccine which is 
a subunit vaccine against hepatitis B surface antigen (HBsAg) (Hourvitz et al. 1996). Higher 
levels of anti-HBV antibodies in individuals vaccinated with CHO-based hepatitis B vaccine 
were recorded in contrast to those vaccinated with yeast-derived Hepatitis vaccine indicating the 








1.6 Blastocystis sp.: a proposed novel candidate for mucosal based vaccine   
 
1.6.1 Blastocystis sp. 
 
Blastocystis sp. is a widely prevalent unicellular anaerobic protozoan that inhabits the 
gastrointestinal tract of humans and different animals (Tan 2008). Blastocystis sp. was found as 
the most frequent protozoa in human fecal samples (Windsor et al. 2002) and has a worldwide 
distribution with prevalence ranging between 30 and 60% (Denoeud et al. 2011). 
 
1.6.2 Blastocystis genetic diversity 
 
In the past, it was believed that one species of Blastocystis infected humans, so it was called 
Blastocystis hominis. On the other hand, other species of Blastocystis infected different animals, 
for example Blastocystis ratti from rats (Noel et al. 2005).  
In 2007, using different genetic analysis, researchers showed that there was no single species of 
Blastocystis which infected humans. In fact, Blastocystis was genetically very diverse. They 
proposed discontinuing the utilization of the term Blastocystis hominis. Their proposal was to 
allude to Blastocystis from humans and animals as Blastocystis sp. subtype nn where nn is a 
number given to the Blastocystis organisms based on the degree of genetic identity as opposed to 
the host that was infected (Stensvold et al. 2007). Ten distinct subtypes (ST1 to ST10) have been 






1.6.3 Life cycle and morphology 
 
Different morphological forms of Blastocystis sp. have been described, including vacuolar, 
granular, amoeboid and cysts. Cyst has been suggested as the infectious stage. However, the life 
cycle of Blastocystis sp. is not clearly known. Cysts will develop into vacuolar form in the 
gastrointestinal tract following their ingestion (Tan 2008). 
 
 
1.6.4 Controversial pathogenicity 
 
 
Blastocystis is a common enteric protistan colonizing the gut of nearly more than one billion 
individuals (Ramirez et al. 2014). The pathogenic capability of Blastocystis sp. has long been a 
subject of debate as the parasite is described in both asymptomatic and symptomatic patients. 
Blastocystis sp. related gastrointestinal disorders include abdominal pains, nausea, diarrhea, 
cramps or urticarial symptoms. It is generally accepted that certain subtypes of the organism are 
virulent (Tan 2008; Sekar & Shanthi 2013).  
A wide range of Blastocystis sp. can infect humans indicating its low host specificity (Noel, 
Dufernez et al. 2005). Blastocystis sp. prevalence in humans often surpasses 5% in industrialized 
countries, and can achieve as high as 76% in developing countries. The likelihood of Blastocystis 
sp. in bringing about human disease is often controversial. However, it could cause ailment in 






1.7 Objectives of this study 
 
Since EV71 is a major cause of severe HFMD, vaccine development against EV71 is considered 
the most effective approach to prevent the EV71 outbreak. VP1 protein is a major immunogenic 
capsid protein of EV71 which has been the target for recombinant vaccine development (Wang, 
Jiang et al. 2013).  
Given the fact that EV71 naturally infects mammalian cells, it seems logical to recombinantly 
produce the VP1 utilizing eukaryotic expression system. Eukaryotic system, as opposed to 
bacterial systems, is able to give rise to proper protein folding and post-translational 
modifications of VP1, which are important for its complete immunogenicity activity. 
This study aims to explore the feasibility of VP1 antigen production in two novel expression 
systems, i.e. CHO and Blastocystis sp. cells, for vaccine development against EV71. Considering 
the successful example of polio vaccines which two vaccine strategies, parenteral and mucosal, 
were used synergistically to prime protection in children, we attempt to model the polio 
vaccination approach for HFMD: (1) parenteral vaccination (subunit): CHO-based VP1 
production; (2) oral vaccination (recombinant vector): Blastocystis-based VP1 production 





Figure 3. Schematic diagram for the HFMD vaccine development approaches in this project. 
CHO and Blastocystis cells were selected for production of VP1 antigen of EV71. 
 
 
In the first approach, recombinant VP1 production will be investigated as secreted form in CHO 
cells for subsequent purification and administration as an injectable subunit vaccine to stimulate 
systemic immunity. Extracellular production of recombinant protein is advantageous than 
periplasmic production to facilitate scale-up protein purification. 
CHO cells were selected for VP1 protein expression due to the following reasons: (1) CHO cells 
are established host cell lines for regulatory approvals of protein expression (Kim, Kim et al. 
2012); (2) CHO derived hepatitis B vaccine was shown to be effective in children (Zhang et al. 
2011; Wang et al. 2015). 
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In the second approach, Blastocystis sp., a commensal enteric protozoan, was selected as a novel 
and promising carrier system. The choice of Blastocystis sp. is essentially due to the following 
rationales: (1) EV71 mostly initiates infection via the gut mucosal surface and spreads via oral-
fecal route (Premanand, Prabakaran et al. 2013). (2) Blastocystis sp. is naturally capable of 
colonizing, proliferating and provoking the immune response in the gut (Teo et al. 2014).  
Based on these two facts, we hypothesize the potential use of Blastocystis sp. as a live carrier to 
express and deliver the EV71 VP1 antigen in the gut such that it may stimulate the gut mucosal 
immunity against EV71infection. Controversial pathogenicity of Blastocystis in human could be 
a speculative concern for future application of Blastocystis-based vaccine in children. However, 
firstly, this study investigates the feasibility of heterologous protein expression in Blastocystis 
system as a proof-of-concept study. Secondly, further mucosal immunogenicity evaluation of 





2 CHAPTER 2: MATERIALS AND METHODS  
 
2.1 Overview of the methodology  
 
Our vaccine development approaches are divided into four phases as illustrated in Figure 4: (1) 
Engineering and construction (cloning) of a series of expression vectors carrying GFP and VP1; 
(2) Expression optimization of rVP1 in CHO and Blastocystis sp. cells; (3) Mice immunization 
and challenge study; and (4) Vaccine refinement. However, given that the approaches 
are still for the most parts highly exploratory, this thesis, within the time limit, centered upon 















2.2 Culturing Rhabdomyosarcoma (RD) cells 
 
 




 CCL­136™) were grown in minimum essential media (MEM) (Life 
Technologies, USA) supplemented with 1% sodium bicarbonate, 2% HEPES, and 20% FBS 
according to the established SOP in our lab. RD cells were passaged every 3-4 days when the 
confluency reached around 80-90% as followed.  
Spent culture medium was discarded. The cell monolayer was rinsed twice with sterile 1X PBS 
to remove all traces of serum followed by adding 2 ml pre-warmed 1X Trypsin-EDTA solution 
(Gibco, USA) until cells rounded up and detached (usually within 5-8 min). 8 ml pre-warmed 
fresh complete growth medium was added to the trypsinized cells and the cell suspension was 
split into new culture flasks containing pre-warmed fresh medium with a sub-cultivation ratio of 
1:2 to 1:4 and incubated at 37°C in a 5% CO2 humidified incubator.  
 
 
2.2.2 Cryopreservation of cells 
 
RD cells were cryopreserved to maintain them at a low passage number. The pelleted cells from 
a confluent T75 flask were resuspended in 1 ml freeze medium (95% complete growth medium + 
5% DMSO) and transferred to a cryovial. The cryovial was placed in Mr Frosty at -80°C for 






2.3 EV71 virus propagation and stock preparation  
 
EV71, Strain 41 (5865/Sin/000009), subgenogroup B4, GenBank Accession no. AF316321, 
initially isolated from a deadly human encephalitis case during an HFMD outbreak in Singapore 
in 2000 (Singh et al. 2002b) was used in this project. The virus was propagated in 
Rhabdomyosarcoma (RD) cells as followed:  
A confluent 75cm
2
 culture flask of RD cells monolayer was rinsed once with sterile phosphate 
buffered saline (PBS) and replaced with fresh complete growth medium. A volume of 500 µl of 
EV71 suspension was added onto the cell monolayer. RD cells were allowed to adsorb the virus 
by incubating the flask at 37°C for 1 hr with rocking at 15 min intervals. Infected culture was 
incubated at 37°C and monitored for cytopathic effect (CPE), which was a result of virus-
induced cell lysis. The culture supernatant, containing the virus, was harvested and centrifuged at 
12,000g for 15 min at 4°C to remove cellular debris and transferred to new cryovials for storage 
at -80C (Khong et al. 2011). 
 
 
2.3.1 Virus purification and inactivation  
 
Virus infected culture supernatants were harvested and clarified from the cell debris by 
centrifugation at 12,000 ×g for 15 min at 4°C. The resulted cleared supernatant was then filtered 
through a 0.65-μm pore size membrane for effective removal of any remaining cell debris and 
further concentrated using Amicon 100 K tube (Millipore). The concentrated virus suspension 
was inactivated by heating at 65°C for 2h. The amount of viral protein was quantified by the 
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Bradford method using the commercially available Bradford assay kit (Bio-Rad Laboratories, 
USA) according to the manufacturer’s instructions. The inactivated concentrated virus was 
stored at -80°C for later use (Liu et al. 2011b). 
 
 
2.3.2 TCID50 for virus titer determination 
 
The infectious virus titer was measured by 50% Tissue Culture Infective Dose (TCID50) based on 
typical cytopathic effect (CPE) caused by EV71 viruses in RD cells. Briefly, RD cells were 
seeded in a sterile 96-well, flat-bottom microtiter plate (Costar Corning, USA) at a concentration 
of 50,000 cells per well and incubated at 37C with 5% CO2 overnight. The next day, the cells 
were infected with 10-fold serial dilutions of the virus in quadruplicate for each virus dilution 
and incubated at 37°C with 5% CO2. The cells were monitored under the inverted microscope 
within 2-5 days post-infection to observe for CPE. TCID50 of the virus is determined as the 
highest dilution of virus giving CPE in 50% of the inoculated cells using Karber formula: 
Log TCID50 = L-d (S-0.5) = -x 
L = Log of the lowest dilution used in the test 
d = difference between log dilution steps  
s = sum of proportion of ‘positive’ tests (culture showing CPE) 
Virus titer = 10x / 25 µl 
(Accuracy of the titration could be increased by using 4 wells per virus dilution) 
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2.4 Workflow on the construction of VP1 expression plasmids   
 






                                                   
                                                      
                                                      
                                                      




Plasmid scale up 
Sequencing 
 























2.5 Viral genomic RNA extraction 
 
Viral genomic RNA was extracted from the culture supernatant of the EV71 infected RD cells 
using the QIAamp
®
 Viral RNA Mini Kit (Qiagen, USA) according to the manufacturer’s 
guideline. Briefly, the culture supernatant was mixed thoroughly with the provided lysis buffer 
and incubated at room temperature for 10 min for the lysis of viral particles. Viral RNA would 
then bound to the silica-gel based membrane and this was followed by washing to remove any 
contaminating proteins and lipids. The bound RNA was eluted with RNase-free water. The RNA 
concentration was measured by Nano-drop
®
 and stored at -80°C till further use. 
 
   
2.6 Reverse Transcription PCR amplification (cDNA synthesis) 
 
Reverse Transcription (RT reaction) was performed to reverse transcribe the extracted viral 
single-stranded RNA into complementary DNA (cDNA) using MMLV-RT
®
 (Invitrogen, USA).   
In brief, 1µg viral RNA was mixed with 1µL random (hexamer) primers and nuclease-free water 
in 15µL reaction volume and incubated at 70°C for 5 minutes. Ten microliters reverse 
transcription master mix was added to the mixture and incubated at 37°C for 1 hour. The reaction 
was heated at 70°C for 15 minutes to inactivate the enzyme. The resulting cDNA was used as 









All the primers used in this project (Table 2) were purchased from IDT (Coralville, USA). 
Kozak sequence was incorporated into the forward primers to enhance translation initiation.  
 
Table 2. Nucleotide sequences of primers used in this project. 
Primer ID Individual primer name Nucleotide Sequences (5′ - 3′) 
P1 BLGMNSP_F   ACCATGAAAGTGCGTCATCGTG 
P2 BLGMNSP/VP1_R   ACTCTATCTCCCTTATCGGCAAGGGCA 
P3 BLGMNSP/VP1_F   CTTGCCGATAAGGGAGATAGAGTGGCA 
P4 VP1_F GGAGATAGAGTGGCAGATGT 
P5 VP1_R  GAAGGGTAGTAATGGCAGTACGAC 




P8 CHADIPOQSP/VP1_F  
 
CAACCATGCTGAGGGAGATAGAGTGGCA 













2.8 Polymerase Chain Reaction (PCR) for generation of single fragments 
 
In order to clone the various fragments into expression vector pcDNA3-GFP, they were first 
amplified by polymerase chain reaction (PCR) method using the primer pairs as shown in Table 
3. 
 
Table 3. Primer pairings and expected product size 
Fragment Primer pairing Expected amplified size (bp) 
VP1 P4; P5 890 
LGMNSP P1; P3 122 
ADIPOQSP P6; P8 79 
LGMN-VP1 P2; P5 904 





 Green Master Mix (Promega, USA) was used to carry out all PCR reactions according 
to the instructions supplied by the manufacturer. The cycling conditions were as followed: 2 min 
at 95°C for the initial denaturation step, 30 cycles of  30 s at 95°C for denaturation, 30 s at 52°C 








2.9 Identification of adiponectin signal peptide for secretion in CHO  
 
Adiponectin signal peptide (ADQ SP) is a commonly used SP when aiming to produce the 
highest possible amount of recombinant protein in a mammalian expression system (Dalamaga et 
al. 2012). CHO adiponectin amino acid sequence was retrieved from NCBI GenBank (Accession 
no.XM_003508212.2). Multiple amino acid sequence alignment of CHO adiponectin protein 
with other vertebrate species was conducted using ClustalW. Prediction of CHO adiponectin 
signal peptide (CADQ SP) was preformed using TargetP online software 
(http://www.cbs.dtu.dk/services/TargetP/). Figure 6 illustrates the alignment and prediction of 
















Figure 6. Sequence alignment and prediction of CHO adiponectin signal peptide 
 
 
2.10 Identification of legumain signal peptide for secretion in Blastocystis 
 
Blastocystis legumain (LGMN) has been shown to be a highly likely secretory protein localized 
on the surface of Blastocystis (Wu et al. 2010a). Blastocystis LGMN amino acid sequence was 
retrieved from NCBI GenBank (Accession no. GU124590.1). Multiple amino acid sequence 
alignment of Blastocystis legumain protein with other species was conducted using ClustalW. 
Prediction of legumain signal peptide (LGMN SP) was preformed using TargetP online software 
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(http://www.cbs.dtu.dk/services/TargetP/). Figure 7 illustrates the alignment and prediction of 






Figure 7. Sequence alignment and prediction of Blastocystis legumain signal peptide 
 
 
2.11 Overlapping PCR for generation of fused fragments 
 
Overlapping PCR was used to generate fused fragments (signal peptides to VP1). The PCR 
products were first purified from PCR mixtures using NucleoSpin PCR Clean-up kit (Macherey-
Nagel, Germany) and mixed in a molar ratio of 1:1 as the DNA template for carrying out 
overlapping PCR. PCR amplification steps were carried out with high fidelity proofreading 
polymerase enzyme, KOD DNA Polymerase (Millipore, USA) according to manufacturer’s 
instruction.  
The LGMNSP (122 bp) and ADIPOQSP (79 bp) fragments were paired with VP1 fragment 
( 890 bp) in overlapping PCR reaction to generate fused fragments LGMN-VP1 (904 bp) and 
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ADIPOQSP-VP1 (905 bp), respectively. As illustrated in Figure 8, the pairing fragments contain 
overlapping regions which anneal together and facilitate the formation of fused fragments after 
repeated cycles of PCR amplification. 
Generated fused fragments LGMN-VP1 and ADIPOQSP-VP1 were checked by agarose gel 
electrophoresis. Respective bands were then excised from the agarose gel and purified for 










2.12 Construction of plasmids 
 
 
2.12.1 Construction of GFP fusion expression vectors via TOPO cloning 
 
For construction of GFP fusion expression vectors, the amplified fragments (VP1, SP-VP1) were 
ligated into the pcDNA3.1/CT-GFP (Invitrogen, USA) using the TOPO
®
 TA Cloning Kit 
(Invitrogen, USA). The pcDNA3.1/CT-GFP vector map is shown in Appendix 1. GFP protein is 
tagged on the c-terminus of the expressed protein and serves as a reporter for instant 
visualization and monitoring of protein expression in CHO and Blastocystis sp. cells. 
As a control to navigate the possible disruptive effect of GFP on the proper folding of VP1 
protein, a construct was created by introducing stop codon before GFP sequence in order to 
terminate the translation before GFP. 
 
 
2.12.2 Subcloning the putative Blastocystis promoters upstream GFP 
 
Since pcDNA3.1/CT-GFP vector is essentially a mammalian expression vector, two additional 
GFP reporter constructs were created by subcloning the putative promoter region of two selected 
native housekeeping genes of Blastocystis sp., namely β-actin (ACTB) and Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). For this, approximately 1kb upstream of the start codon of 
these genes were amplified from Blastocystis sp. genomic DNA (Kindly provided by John 
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Yason) and cloned into pcDNA3.1/CT-GFP vector presuming to drive the gene expression in 
Blastocystis sp. as homologous promoters (Figure 9).  
 
 
Figure 9. Schematic view for construction of Blastocystis promoter-driven expression of GFP 
 
 
2.12.3 Construction of myc/His tags expression plasmid 
 
The pcDNA3.1/myc-His A vector (gifted by Dr Lu Jinhua) was used to create a construct for 
expression of ADQ-VP1 gene fused with myc and a polyhistidine tags to facilitate downstream 
purification of recombinant VP1 via affinity chromatography. The vector map is provided in 
Appendix 2.  
To create the pcDNA3.1-VP1-myc-His construct, ADQ-VP1 fragment was first generated by 
PCR using primers P6 and P9 (Table 2) and subsequently digested with restriction enzyme ApaI 
(New England Biolabs, USA) according to manufacturer’s recommendations. Digestion of the 
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pcDNA3.1/myc-His A vector was performed with EcoRV to open up and generate blunt 5' end 
followed by second digestion with ApaI to generate sticky 3' end. 
A schematic illustration of the restriction digestion and ligation steps is shown in Figure 10. 
 
 
Figure 10. Construction of the ADQ-VP1-myc-His vector for expressing the myc/His-tagged 
VP1 in CHO cells. 
 
 
2.13 Agarose gel electrophoresis 
 
Each amplified product to be analyzed was mixed with 6X loading dye (Life Technologies, 
USA) before loading into either 4% TBE agarose gel for less than 100 base pairs (bp) products 
or 1.2% TAE gel for greater than 1 kilobase (kbp) products and were electrophoresed for 3h at 
70V and 1h at 120V, respectively. Appropriate DNA ladders, 10 bp DNA ladder (Promega, 
USA) for fragments less than 100 bp and 1 kbp DNA ladder (Thermo Fisher Scientific, USA) for 
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fragments greater than 1kb were used for estimation of band size. All gels were stained with 
SYBR Safe (Life Technologies, USA) and visualized under ChemiDoc
™
 MP System (Bio-Rad, 
USA).  
Both digested insert and vector were electrophoresed on agarose gel and the respective DNA 
bands were excised and purified from the gel with GeneJET PCR Purification Kit (Thermo 
Fisher Scientific) as per manufacturer’s recommendations. Subsequently, 50ng of both the 
digested insert and vector were ligated using 3U of T4 DNA Ligase (Thermo Fisher Scientific, 
USA) incubated at room temperature for 2h.  
 
 
2.14 Chemical transformation of chemically competent E. coli 
 
Five microliters of ligation mix was added to a vial of One Shot
®
 TOP 10 chemically competent 
E. coli cells (Invitrogen, USA) and mixed gently. The DNA-competent cells mixture was 
incubated on ice for 30 min, followed by a heat shock at 42ºC for 45 seconds. The tube was then 
immediately placed on ice for 2 min. Two hundred fifty microliters LB medium without 
antibiotics was added to the mixture and incubated at 37ºC for 1 h with shaking. This was 
followed by plating 50 μl transformation mixture onto pre-warm LB agar supplemented with 







2.15 Colony PCR screening for successful ligations 
 
Colony PCR was performed to screen for positive transformants. This technique was used to 
rapidly test for the presence of the insert, its expected sizes and orientation in the plasmid.  
Using a micropipette tip, 10 single colonies were picked off the transformation plate, pin-pricked 
to a replica plate to preserve the colonies for further analysis. This was followed by flushing into 
20 µl of the GoTaq
®
 Green Master Mix (Promega, USA) (Figure 11). 
 
 
Figure 11. Schematic illustration of Colony PCR protocol. 
 
For PCR primers, T7 forward sequencing primer provided in the TA TOPO cloning kit with VP1 
reverse internal primer were used (Table 4).  
Colony PCR products were loaded on 1.2% agarose gel and electrophoresed for 1 h at 120V. 
After visualization of gel under ChemiDoc
™
, the corresponding desired colonies were retrieved 
from the replica plate and then inoculated into 5ml LBA medium in snap cap tubes for overnight 










Table 4. Nucleotide sequences of forward and reverse primers used for colony PCR 
primer Nucleotide Sequences (5′ - 3′) 
T7_F :  TAATACGACTCACTATAGGG 
VP1 internal_R TTCCTGCTATCCGGCTTAGG 
 
 
2.16 Plasmid isolation extraction  
 
Overnight culture tubes were removed after 16 h incubation. Plasmid DNA was isolated using 
Wizard Plus Miniprep DNA Purification Kit (Promega, USA) according to the protocol 
recommended by the manufacturer. 
Concentration and purity of the extracted DNA plasmids were quantified using the NanoDrop 
ND-1000 Spectrophotometer. Plasmids were stored at -20°C till further use. 
 
 
2.17 DNA sequencing analysis 
 
Constructed plasmids were sent for DNA sequencing using ABI PRISM3100 Analyzer (Applied 
Biosystems, USA) located at DNA sequencing facility, Department of Microbiology, NUS with 
forward sequencing primer (T7 sequencing Primer) and reverse sequencing primer (GFP reverse 
primer) provided in CT-GFP Fusion TOPO
®
 TA Expression Kit (Invitrogen, USA). The 
sequencing results were examined through online BLAST program 
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(http://www.ncbi.nlm.nih.gov/BLAST/) to confirm the sequences and orientation of the insert in 
the plasmids. In addition, the cloned fragments were checked carefully to ensure it is in frame 
with GFP for subsequent expression of GFP fusion protein. 
 
2.18 Scaling up the plasmids  
 
After confirming the accuracy of constructed plasmids with DNA sequencing analysis, the 
relevant clones were picked from the replica plates and inoculated into 100ml LB broth 
containing 100 µg/ml ampicillin. The cultures were incubated overnight at 37°C with shaking at 
230 rpm. The next day, first 500 µl of each bacterial culture was mixed with 50% filtered 
glycerol in a 1:1 ratio in a cryovial (glycerol stock preparation) and stored at -80°C for long term 
storage of the clones. The bacterial cells were then harvested by spinning at 5000g for 20 min at 
4°C. Plasmids were purified using the EndoFree
®
 Plasmid Maxi Kit (QIAGEN, USA) following 
the manufacturer’s protocol. The DNA pellets were resuspended in 100 µl endotoxin-free buffer 
TE and stored at -20°C till further use for transfection experiments. 
 
 
2.19 Workflow on the protein expression in CHO cells 
 










2.20 Chinese Hamster Ovary (CHO) cell culture 
 
CHO-K1 cell line (ATCC
®
 CCL­61™) was cultured in F-12K medium supplemented with 10% 
fetal bovine serum (FBS) (BioWest, France) at 37°C incubator with 5% CO2 in the atmosphere. 
CHO cells were subcultured every 3-4 days. Low passage number cells (less than 20) were used 






2.21 Transfection of CHO cells 
 
The day before performing the transfection, CHO cells were seeded at a cell density of 
approximately 130,000 to 280,000 cells/ml into each well of a 6-well plate with F-12K medium 
supplemented with 5% FBS and incubated at 37°C overnight. This plating density was found to 
be appropriate based on our experience in relation to the sensitivity of CHO cells to contact-
inhibition.   
Upon reaching 70% confluency, CHO cells were transfected with a transfection mixture 
containing 2μg of plasmid DNA diluted in Opti-MEM® reduced-serum medium (Gibco, USA) 
and Lipofectamine
®
 3000 reagents (Invitrogen, USA) as per manufacturer’s protocol. Mock-
transfected cultures (No plasmid but transfection reagent added) were included in each 
transfection experiment as the negative control. GFP expression control vector (pcDNA3.1/CT-
GFP) was also included in each transfection plate as the positive control to check both 
transfection efficiency and expression of the plasmids. 
After 48 h incubation at 37°C, each well was observed by EVOS
®
 fluorescent microscope 
(Advanced Microscopy Group, USA). Transfection efficiencies were calculated by enumerating 
the fluorescent CHO cells as percentage of the total cell population. 
 
 
2.22 G418 (Geneticin®) antibiotic selection for transfected CHO  
 
In order to find the most efficient concentration of antibiotic G418 for selection of transfected 
CHO cells, different concentrations (0-1000 µg/ml) of G418 (Geneticin
®
) (Life Technologies, 
USA) were tested on growing CHO cells until 100% cell death reached in untransfected cells 
within one week. The procedure was as followed: CHO cells were seeded at a density range of 
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0.8–3.0 × 105 cells/ml in 0.5 ml F12K plus 2% FBS per well in a 24-well tissue culture plate one 
day prior to introducing G418 selection. Duplicate wells of CHO cells seeded in 24-well plate 
were added with 0, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, and 1000 µg/ml of G418 
respectively. Media containing the relevant G418 antibiotic was replaced every 2-3 days. Cells 
were visualized under inverted microscope for signs of toxicity. The lowest G418 concentration 
at which all cells were dead after one week of antibiotic selection was considered as the efficient 
killing concentration of G418 for CHO cells.  
 
 
2.23 Harvesting CHO cell lysates and supernatants 
 
After maintaining the transfected CHO cells under selection pressure with effective killing 
concentration of G418 in 6-well plate for 7 days, successfully transfected cells survived due to 
their antibiotic resistance. The cell culture supernatants were then collected and centrifuged at 
13,000 rpm for 20 min at 4°C to remove cellular debris. After that, supernatants were transferred 
to fresh microtubes and stored at -20°C. 
The remaining attached CHO cells were rinsed with cold 1X phosphate buffered saline (PBS) 
twice prior to addition of 200 µl M-PER mammalian protein extraction reagent per each well. 
Cells were incubated for 5 min by gentle shaking to complete the cell lysis. After that, lysed cells 
were scraped off the well using disposable cell scraper and transferred to prechilled microtubes. 
The mictotubes were swayed on nutating mixer in cold room for 30 min followed by 
centrifugation at 13,000 rpm for 15 minutes at 4°C. Cleared cell lysates were transferred to new 
microtubes and stored at -20°C for later western blot analysis. Total protein concentration was 
quantified using Bradford Protein Assay Reagent (Bio-Rad, USA) according to manufacturer’s 
instructions. The absorbance of the reaction mixture was measured at 595 nm after 15 min of 
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incubation at room temperature. A range of bovine serum albumin (BSA) (Santa-Cruz 
Biotechnology, USA) from 0.1 to 1 mg/ml was used as the standard. 
 
 
2.24 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Total protein separation was performed under denaturing conditions via SDS-PAGE using 
Bio-Rad Mini-PROTEAN
™
 gel system. The polyacrylamide gels were casted as a 10% 
polyacrylamide resolving gel and a 4% polyacrylamide stacking gel both containing 10% SDS as 
indicated in Appendix 3.  
Cell lysate and supernatant samples (50 µg of total protein) were mixed with 5X sample buffer 
(SB) containing 2-mercaptoethanol (2ME), and heated at 95°C for 5 min immediately before 
loading onto the gel. 
Five microliters of PageRuler Prestained Protein Ladder (Thermo Fisher Scientific, USA) was 
run in one lane of the gel as the size marker. Electrophoresis was carried out in 1x Tris-Glycine 
SDS Running Buffer at 120 V until the front line dye reached near the end of the gel which took 
around 1h 45 min.  
 
 
2.25 Western blot analysis  
 
After SDS-PAGE, the separated proteins were electro-transferred from gels onto polyvinylidene 
difluoride (PVDF) membranes (GE Healthcare, UK) at 300mA for 1 hour using wet transfer 
system (Bio-Rad, USA). Methanol-Tris-Glycine (192 mM glycine, 25mM Tris HCl (pH 8.8), 
20% methanol (v/v)) was used as the transfer buffer. Before blotting, PVDF membranes were 
activated by soaking in methanol for 10 seconds.  
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After transferring proteins from gels onto membrane, the blots were immersed in sufficient 
Ponceau S staining solution (Sigma-Aldrich, USA) and stained for 5 min to reveal the protein 
profile. Stained blots were then washed with 1X Tris-buffered saline with Tween-20 (TBST) 
buffer to remove the Ponceau S stain before blocking with 5% nonfat milk in 0.1% TBST for 1h 
at room temperature with agitation. Appropriate primary antibody (Table 5) diluted in 1% BSA-
TBST (w/v) was added to blocked membranes and incubated overnight in cold room on a 
rocking shaker.  
Next day, the blots were washed with 1X TBST for 5 times of 5 minutes each with shaking at 
room temperature.  
After washing, the blots were incubated with the appropriate HRP conjugated secondary 
antibody (Table 6) diluted in 1% BSA-TBST for 1h at RT with gentle agitation. The blots were 
then washed with 1X TBST for 5 times of 5 minutes each. HRP chemiluminescent substrate 
(WesternBright ECL, Advansta, USA) was added onto the membranes in sufficient amounts (0.1 
ml/cm
2
) to cover the full surface evenly for 2 min. After that, imaging was performed in the dark 
room by exposing the blots with X-ray films (Fujifilm, Japan) and subsequently developed in X-










Table 5. Primary antibodies used in western blot experiments in this thesis. 
No. Primary Antibody Description Dilution 
1 Anti-VP1 mAb (Abnova, Taiwan) mouse, monoclonal, specific to EV71 
VP1 
1:1000 
2 Anti-VP1 mAb (Abcam, USA) mouse, monoclonal, specific to EV71 
VP1 
1:1000 
3 Anti-VP1 pAb (Abcam, USA) mouse, polyclonal, specific to EV71 VP1 1:1000 
4 Anti-VP1 mAb  (LSBio, USA) mouse, monoclonal, pan-enterovirus 1:1000 
5 Anti-myc mAb (Thermo Fisher 
Scientific, USA) 
mouse, monoclonal 1:1000 
6 Anti-His mAb (Thermo Fisher 
Scientific, USA) 
mouse, monoclonal 1:1000 
7 Anti-GFP pAb (Invitrogen, USA) rabbit, polyclonal 1:1000 
 
 
Table 6. Secondary antibodies used in Western Blot. 
Secondary Antibody Description Dilution 
goat anti-mouse IgG-HRP (Santa Cruz Biotech) Used with mouse raised primary Abs 1:3000 








2.26 Blastocystis work 
 
2.26.1 Blastocystis sp. culture 
 
Blastocystis sp. subtype 7 isolate B, previously isolated from a patient at Singapore General 
Hospital (Ho et al. 1993), was used in this project. Cells were cultured in 6 ml of prereduced 
Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% heat- inactivated horse 
serum with incubation at 37 °C under anaerobic condition generated by AnaeroGen gas pack 
(Oxoid, UK) inside an Anaerojar (Oxoid, UK). Cells were subcultured every 3-4 days and 4-day 
old cells at log-phase were used for transfection experiments. 
 
 
2.26.2 Susceptibility testing of Blastocystis against G-418 by Resazurin Microassay 
 
Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) viability assay was performed to 
determine the effective killing concentration of antibiotic G418 for selection of transfected 
Blastocystis sp. In brief, 10
6
 Blastocystis sp. cells were incubated in a final volume of 200 μl per 
well of 96-well plate and incubated at 37°C under anaerobic conditions for 24 h. A 5% Resazurin 
dye solution (Sigma-Aldrich, USA) was added to each well. After 3h incubation, resazurin 
fluorescence was measured at 550 nm excitation and 570 nm emission wavelengths, using Tecan 







2.26.3 Transfection of Blastocystis sp. by electroporation  
 
No transfection system for Blastocystis sp. has been reported previously. Electroporation 
protocols published previously for other protozoa were followed. Table 7 lists the starting 
conditions used for conducting electroporation on Blastocystis. Trial-and-error optimization 
electroporation experiments were carried out with varying a single key parameter while 
maintaining other parameters constant. 
Blastocystis cells were harvested from 3-4 day culture tubes, washed once with phosphate 
buﬀered saline (PBS) and resuspended in electroporation buﬀer at a density of 108 parasites/ml. 
Then, 100-200 µg of plasmid DNA (pcDNA3-GFP, pcDNA3-β-actin pmr-GFP or pcDNA3-
GAPD pmr-GFP) was mixed with 800 µl of cell suspension in an ice cold electroporation cuvette 
(0.4-cm gap) (Bio-Rad, USA) and electroporated using Bio-Rad Gene Pulser Xcell
TM
 
electroporator set at the desired parameters. The cells were immediately recovered into 6ml of 
fresh pre-reduced IMDM medium supplemented with 10% horse serum and 200 µg/ml G418 in 
culture tubes and incubated anaerobically at 37 °C.  
After incubation for 3 days, the electroporation's effect on cell viability was evaluated by visual 
examination of cell pellet growing and color change of overlay medium. Mock-transfected 
Blastocystis sp. cultures (electroporated Blastocystis without plasmid addition) was included in 
each electroporation experiment as the control. Analysis of GFP expression was performed at 






Table 7.  Different electroporation conditions tested on Blastocystis using Bio-Rad Gene Pulser 
Xcell
TM
 Electroporation System 
Electroporation condition Electroporation 
buffer 
Previously published for: 
350 V, 1000 µF, and 720Ω cytomix buffer* Giardia lamblia (Davis-Hayman & Nash 
2002) 
0.3 kV, 500 µF, 2 pulses 
(10s betwen), 3.0- 6.0 ms 
time constant 
cytomix buffer Trypanosoma cruzi (DaRocha et al. 2004) 
3000 V/cm, 25 µF, 0.4 ms 
time constant 
cytomix buffer Entamoeba histolytica (Nickel & Tannich 
1994) 
1500V, 25 µF,  50Ω cytomix buffer Toxoplasma gondii (Zhang et al. 2013) 
* Cytomix buffer: 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4, 25 mM Hepes, 2 mM 
EDTA, 5 mM MgCl2, pH 7.6 
 
 
2.26.4 Confocal microscopy for GFP expression analysis 
 
At day 3 and 6 post transfection, Blastocystis sp. cells were washed once in PBS, and mounted 
on glass slides under coverslips. Transfected cells were examined for green fluorescence 
utilizing standard FITC excitation/emission filters (395/507 nm) under a confocal microscope 
(Olympus Fluoview FV1000, Japan) with a 100X objective. Laser power between 1% and 30% 
was used. 
Mock-transfected culture was first used to adjust the parameters such that the high background 
(auto-fluorescence) was suppressed to its minimum level. Then all samples were imaged; five 
random images were captured. Optimization to find the best filter sets to detect the GFP 
fluorescence with brighter signal was carried out. At least 250 cells were examined for GFP 
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fluorescence signal, and the transfection success was assessed as percentage of GFP positive 
cells between mock and transfected Blastocystis cells. 
 
 
2.26.5 Flow cytometry for GFP expression analysis 
 
After the transfection of Blastocystis sp. with GFP-containing plasmids, GFP fluorescence 
intensities in transfected cultures were enumerated using flow cytometry analysis 3 to 6 days 
post- transfection. 
The cells were washed with phosphate-buffered saline (PBS) by centrifugation at 1000 ×g for 10 
min and resuspended with phosphate-buffered saline immediately before flow cytometry 
analysis. Flow cytometry analysis was performed on a population of 10,000 cells by using a LSR 
Fortessa Analyzer (BD Biosciences, USA). Gating was performed on live single cell 
subpopulation based on forward- and side-scattering parameters and numerical data were 
processed using commercially available software package FlowJo (Tree Star, USA). Mock-
transfected Blastocystis sp. culture (electroporated cells without addition of plasmid) was 




3 CHAPTER 3: RESULTS 
 
 
3.1 Overlapping PCR products for generation of fused fragments 
 
Fusion of adiponectin and legumain signal peptides to VP1 gene via overlapping PCR strategy 
was analyzed on agarose gel electrophoresis (Figure 13) prior to gel-purification of respective 
bands for ligation into expression vectors.  
 
 








3.2 Construction of expression plasmids 
 
Standard molecular cloning techniques were utilized to construct the expression plasmids. As 
listed in Table 8, multiple mammalian expression plasmids, using parental pcDNA3.1/CT-GFP 
and pcDNA3.1 myc/His A vectors, were constructed in order to compare their efficiency of 
protein production in CHO and Blastocystis. 
Signal peptide of adiponectin and legumain native proteins were employed to direct the 
extracellular production of VP1 in CHO and Blastocystis, respectively.     
As there are no precedent of suitable expression vectors designed for Blastocystis, I had cloned 1 
kbp region upstream of the start codon of two native housekeeping genes of Blastocystis, β-actin 
(ACTB) and Glyceraldehyde 3-phosphate dehydrogenase (GAPD) into pcDNA3.1/CT-GFP as 
putative promoters to drive the GFP expression in Blastocystis sp.  
The accuracy of constructed plasmids were confirmed by DNA sequencing.  
A schematic representation of the plasmids created for the expression of VP1 and GFP in CHO 




Table 8. Constructed expression plasmids for CHO and Blastocystis sp. 
No. construct purpose promoter tag 
 CHO constructs    
1 pcDNA3-VP1-GFP periplasmic production of VP1 
fused to GFP tag 
CMV GFP 
2 pcDNA3-ADQSP-VP1-GFP extracellular production of VP1 
fused to GFP tag 
CMV GFP 
3 pcDNA3-ADQSP -VP1 extracellular production of VP1 
without GFP tag  
CMV * 
4 pcDNA3-ADQSP -VP1-myc/His  extracellular production of VP1 





 Blastocystis constructs    
5 pcDNA3-LGMSP-VP1-GFP extracellular production of VP1 
fused to GFP tag 
CMV GFP 
6 pcDNA3-LGMSP-VP1 extracellular production of VP1 
without GFP tag 
CMV * 
7 pcDNA3-ACT pmr-GFP  
 






















     










3.3 Colony PCR for verification of inserts into plasmids  
 
Correct orientation of inserted fragments ADQSP-VP1 and LGMSP-VP1 into the pcDNA3-GFP 
vector was verified by performing colony-PCR on chosen colonies grown in selection plates. The 
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expected band size based on vector specific and internal VP1 primers were observed on agarose 




Figure 15. Colony-PCR screening with T7_F and VP1_R internal primers and agarose gel 
electrophoresis for verification of fragment insertion. Lane M, DNA ladder, Lanes 1-10 




3.4 Transfection efficiency of GFP-containing vectors in CHO  
 
VP1 alone, VP1 fused to adiponectin signal peptide, and VP1 fused to legumain signal peptide 
were successfully cloned into the pcDNA3-GFP plasmid vector and their accuracy were verified 





 3000 (Invitrogen, USA) was used as the transfection method to deliver the 
plasmids into the CHO cells. 
Transfection efficacies of the GFP-carrying constructs in CHO cells were first evaluated by 
visual inspection of GFP reporter under EVOS
®
 fluorescent microscope (Advanced Microscopy 
Group, USA) at 24h, 48h and 72h post-transfection.  
Successful expression of GFP was observed by bright green illumination under flourescent 
microscope from CHO cells transfected with expression control vector (pcDNA3.1/CT-GFP) 
(Figure 16A). This indicates the success of the transfection and expression in CHO cells. 
In contrast to GFP empty vector which encoded intact GFP, other constructs encoding for GFP 
fusion VP1 showed hardly detectable GFP flourescence by visual inspection. Blastocystis 
specific GFP-carrying constructs were also included in CHO expression experiments as controls. 
GFP signal was dim and expression efficiency was found to be less than 10% (Figure 16B-H). In 
spite of maintaining the transfected CHO cells under antibiotic G418 selection, GFP 
fluorescence remained as such even until 7 days after transfection (data not shown). These 
observations could be suggestive of the compromised expression of VP1 in CHO cells when 












Figure 16. Confocal microscopy overlay images for comparative assessment of GFP expression 
efficiency of constructed plasmids in CHO cells. (A) CHO cells transfected with GFP expression 
control plasmid; (B-H) CHO cells transfected with seven plasmids created from pcDNA3.1/CT-
GFP plasmid vector (Invitrogen, USA). Blastocystis specifc constructs (D,E,F,H) were also 
included in CHO transfection experiment as controls. Lipofectamin
®
 3000 were used as 
transfection reagent. Images were captured 72h post-transfection under 20X magnification using 
EVOS
®




3.5 Western blot analyses for expression of GFP-containing vectors in CHO cells 
 
Western blot experiments were carried out by using antibodies specific to EV71 VP1 to check 
the expression of VP1 fused to GFP. CHO cells transfected with constructed GFP-containing 
vectors were kept under antibiotic G418 selection until all untransfected control cells died 
(within 7 days). 
Table 9 shows the expected size of the expressed proteins.   
 
Table 9. Predicted size of the expressed proteins. 







Initially, EV71 VP1 monoclonal antibody (Abnova, Cat. No. MAB1255-M06) was purchased for 
detecting the recombinant VP1 (rVP1) expression. Figure 17 shows the western blot analysis on 
the supernatants (concentrated and non-concentrated) and lysates of transfected CHO cells using 
this antibody. As can be seen, positive control which was the supernatant of EV71 infected RD 
cells showed a band between 34 and 43 kDa (Figure 17A and B, lane 1) which is close to the 
expected size of VP1 (33 kDa). However, this band was also present in mock-transfected cells. 
Therefore, it was difficult to conclude based on the results obtained by this antibody due to 
nonspecific binding.   
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Another notable result was that all the supernatants including mock-transfected CHO cells 
showed bands between 55 kD and 72 kD. The VP1-GFP fusion protein band was expected to be 
present in this area but due to the existence of nonspecific bands in this area, identification 
remained inconclusive.  
We suspected that this band might be as a result of cross-reactivity between the antibody and a 
serum component, most likely serum albumin. To test this possibility, the growth medium of 
CHO cells (F12K) without addition of FBS was included. As seen in Figure 17B lane3, no band 
was observed for F12K which indicates the cross reactivity of the antibody with serum.  
The culture supernatant was concentrated to increase the chance of detection of the expressed 
rVP1 protein. However, our experiments showed that the problem of cross-reactivity between the 
antibody and serum led to stronger black smudge due to high concentration of serum (Figure 






Figure 17. Western blot analysis of the VP1 protein expression in CHO cells transfected with 
constructed GFP containing vectors. Western blot analysis was performed using EV71 VP1 
monoclonal antibody (Abnova, cat #MAB1255-M06) at 1:1000 dilution. EV71 virus-infected 
RD cell supernatant (+) and CHO cells without addition of plasmid (mock) were used as 
controls. Expected VP1 band size is shown by red arrow. 
 
 
Moving on to Anti-VP1 antibody from another vendor, we purchased EV71-specific mAb 
(AbCam #ab36367). Figure 18 shows the western blot analysis on the supernatants and lysates of 
transfected CHO cells using this antibody. As can be seen, this antibody resulted in nonspecific 
bands in the lysates of transfected and mock-transfected CHO cells (Figure 18A) which is hard 
to conclude about the expression of VP1. In the supernatant no specific bands were detected in 





Figure 18. Western blot analysis with EV71-specific mAb (AbCam #ab36367). Antibody was 
used at 1:1000 dilution. EV71 virus-infected RD cell supernatant (+) and CHO cells without 
addition of plasmid (mock) were used as controls. 
 
 
Testing another antibody from the same vendor, EV71-specific pAb (AbCam #ab169442) was 
purchased. Figure 19 shows the western blot analysis on the culture supernatants and lysates of 
transfected CHO cells using this antibody. As can be seen, positive control which was the 
supernatant of EV71 infected RD cells showed a band between 34 and 43 kDa (Figure 19A and 
B, lane 1) indicating the recognition of VP1 of EV71. However, no band could be recognized in 
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the transfected CHO cells. This might suggest that constructs failed to express VP1 or very low 
level of VP1 have been expressed such that it could not be identified by the antibody. 
This antibody also showed cross reactivity with serum since it gave bands between 55 kDa and 
72 kDa in culture supernatants of transfected and mock-transfected CHO cells (Figure 19B). 
Compared to other tested anti-VP1 antibodies, this antibody produced better results in our hands. 
 
Figure 19. Western blot analysis with EV71-specific VP1 polyclonal antibody (AbCam 
#ab169442). Antibody was used at 1:1000 dilution. EV71 virus-infected RD cell supernatant (+) 








3.6 Western blot analysis for expression of myc/His tags vector in CHO cells 
 
The attempts to establish CHO cells expressing VP1 fused to GFP by transfection with various 
GFP-containing vectors failed to show significant expression level. It is likely that GFP fusion to 
c-terminal of VP1 could attribute to the prevention of expression in transfected cells. To test 
another expression vector, VP1 gene fused to adiponectin signal peptide (ADQSP-VP1) was 
cloned in pcDNA3-myc/His vector (Invitrogen, USA), designated as pcDNA3-ADQSP-VP1-
myc/His. This vector is smaller than pcDAN3-GFP vector since it is without GFP tag but with 
myc and 6×His epitope tags instead. Lipofectamine
®
 3000 (Invitrogen, USA) was used for the 
transfection of the constructs into the CHO cells. The growth medium was supplemented with 
antibiotic G418 (Life Technologies, USA) at 800 μg/ml (a concentration that killed G418-
sensitive CHO cells within 1 week of maintenance under selection pressure). Transfected cells 
containing the construct were selected for their ability to break down G418 in growth medium as 
a result of expressing the plasmid-encoded neomycin phosphotransferase.  
Transient expression of pcDNA3-ADQSP-VP1-myc/His construct in CHO cells was checked by 
western blot using EV71-specific VP1 antibody as well as with the complementary anti-tag 
antibodies, namely anti-myc and anti-His.  
For recognition of VP1, we used EV71-specific VP1 polyclonal antibody (AbCam #ab169442) 
since from earlier western blot experiments, we found it to be better for recognition of VP1. 
Myc-His protein tag is predicted to add approximately 2-3 kDa to the expected size of VP1. 
Therefore, the expected size for rVP1 expressed by pcDNA3-ADQSP-VP1-myc/His would be 
around 43 kD. The rVP1 was detected in the lysate of transfected CHO cells as a unique band 
whereas mock-transfected CHO cells did not show any band at this area (20A, red arrow). 
However, other bands with the same pattern in both transfected and mock-transfected were 
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observed at regions 34-43 kDa as well as 43-55 kDa indicating that this antibody showed 
nonspecific binding at those regions.   
Expression of rVP1 in the lysate of transfected cells was also shown by probing the blots with 
anti-myc antibody, which gave a distinct band in transfected cells around 43 kDa close to the 
expected rVP1 (Figure 20B, red arrow). Likewise, anti-His antibody showed unique band around 
43 kDa in transfected CHO cells (Figure 20C, red arrow). Unlike anti-myc antibody, anti-His 
antibody showed nonspecific binding at region 55-72 kDa in both cell lysates of mock and 
transfected CHO cells. 
Interestingly, three separate blots with the same amount of lysates from CHO cells transfected 
with pcDNA3-ADQSP-VP1-myc/His construct showed similar bands around 43 kDa confirming 
the expression of rVP1-myc/His protein.  
This experiment showed that despite loading the same amount of protein and using the same 
antibody dilution, weaker signals were obtained from EV71 VP1 antibody suggesting its lower 
affinity to the expressed protein as compared to complementary anti-tag antibodies. Moreover, 
anti-myc antibody gave the best results since it exhibited the highest signal intensity and the least 
non-specific binding (Figure 20B).   
While all complementary antibodies and EV71 VP1 antibody detected the rVP1-myc/His in cell 
lysates of transfected CHO cells, they showed no band around 43 kDa in the culture supernatants 
(Figure 21). Instead, bands between 55 kDa and 72 kDa were observed across all the lanes 
loaded with mock and transfected cell culture supernatant. These bands suggest cross reactivity 
of the antibodies with a component of serum perhaps the serum albumin.  To test the cross-
reactivity of the serum with the antibodies, CHO growth culture medium (F12K) without 
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addition of FBS included in all experiments as negative control (Figure 21A lane 3; B lane 2, C 
lane 3). As seen, in the absence of serum, no binding occurred.   
The VP1 was fused to the CHO adiponectin signal peptide for the purpose of secretion of rVP1 
outside the CHO cells. However, these results showed that VP1 produced intracellularly rather 
than secreted in the culture medium suggesting that the signal peptide was somewhat inefficient. 
Overall, western blot analysis showed that pcDNA3-ADQSP-VP1-myc/His construct had 
successfully expressing rVP1 in CHO cells. This was verified by three different antibodies (anti-
VP1, Myc and His) with consistent results. Therefore this construct can be used for production of 
rVP1 in CHO cells. Since expressed rVP1 is a His-tagged protein, subsequent purification could 







Figure 20. Western blot analysis of the VP1 protein expression in lysates of CHO cells 
transfected with constructed pcDNA3-ADQSPVP1-myc/His vector. Western blot analysis was 
performed using EV71-specific VP1 polyclonal antibody (AbCam #ab169442) (Blot A), anti-
myc antibody (Blot B) and anti-His antibody (Blot C) at 1:1000 dilution. CHO cells without 






Figure 21. Western blot analysis of the VP1 protein expression in supernatants of CHO cells 
transfected with constructed pcDNA3-ADQSPVP1-myc/His vector. Western blot analysis was 
performed using EV71-specific VP1 polyclonal antibody (AbCam #ab169442) (Blot A), anti-
myc antibody (Blot B) and anti-His antibody (Blot C) at 1:1000 dilution. CHO cells without 





3.7 Optimal electroporation conditions for Blastocystis sp. 
 
Up until now no transfection protocol for Blastocystis sp. was reported in the literature. 
Electroporation was used as a routine method in this project for gene transfection in Blastocystis 
sp. based on the already described electroporation protocols for other protozoa from different 
literature studies (material method, Table 7).  
Initially, the optimal electroporation conditions for Blastocystis sp. were required to be 
determined empirically. Cell viability was assessed qualitatively by cell pellet growing at the 
 72 
 
bottom and change of overlay medium (red to yellow) in culture tubes 3 to 6 days after 
transfection. 
Table 10 lists the tested key electroporation parameters and obtained optimal conditions that 
yielded higher cell viability after many rounds of trial-and-error electroporation experiments on 
Blastocystis sp. 
 
Table 10. Optimized electroporation conditions that resulted in higher viability of Blastocystis 
Parameters  Testing range Optimal 
conditions 
Pulse form   square wave and exponential decay 
 
square wave 
Voltage 100-3000V 1500 V 
Pulse Length 
 
0.5-30 msec 0.5 msec 










10-200 µg/µl 200 µg/µl 









3.8 Confocal microscopy analysis of GFP expression in Blastocystis sp. 
 
Viability of transfected Blastocystis cells was first evaluated by visual inspection of pellet 
growing and color change of overlay medium (red to yellow) at least 3 days after 
electrotransfection. Then, GFP expression in electroporated Blastocystis cells was also assessed 
by visualization of green fluorescence under Olympus Fluoview FV1000 confocal microscope 3 
and 6 days after electroporation. A mock transfected culture (electroporated Blastocystis without 
addition of plasmid) was included in each electroporation experiment. The auto-fluorescence 
(background) was found to be high. The confocal microscope settings were adjusted based upon 
mock transfected cells to eliminate the background fluorescence; but this had also compromised 
the signal from GFP. 
To enhance the visualization of GFP fluorescence, identical post processing modification 
including adjustments of contrast (-40 %) and sharpness/brightness (+40 %,) was introduced 
across all images to improve the fluorescent signal.  
Figure 22 shows confocal micrographs of Blastocystis cells that were transfected with 200 μg of 
each plasmids. As can be observed, low signal green fluorescence distributed either throughout 
or at the outer edge of the cells was detected in some cells. However, no distinguishable 
differences on fluorescence were observed between positive transfection control (pcDNA3-GFP) 
and mock transfected Blastocystis cells (Figure 22A and B).  
In addition, constructs carrying putative promoter regions of native housekeeping genes β-actin 
and GAPDH of Blastocystis, designated as pcDNA3-ACT pmr-GFP and pcDNA3-GAPD pmr-
GFP respectively exhibited no obvious increased GFP expression (Figure 22C and D).  
GFP fluorescence was analyzed in the presence of 200 µg/ml antibiotic G418 for selection, and 
remained as such 6 to 9 days after the initial electroporation (data not shown). It was, therefore, 
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suggesting that these promoters did not work efficiently to drive the expression of GFP at a 
visible level.  
Considering the existence of Blastocystis cytoplasm as a thin rim located around the large central 
vacuole of the cells together with low level of GFP expression, it can be speculated that the real 
case of GFP fluorescence might be hard to detect under confocal microscopy which was further 













Figure 22. Representative confocal microscopy images illustrating the Blastocystis cells 
electroporated with constructed GFP-containing plasmids (1000X magnification). Blastocystis 









3.9 Flow cytometry analysis of GFP expression in electrotransfected Blastocystis sp. 
 
Since GFP expression was found to be somewhat very low when transfected Blastocystis cells 
were examined visually under confocal microscope, flow cytometry experiments were carried 
out in similar time courses (3 and 6 days) after electroporation. Flow cytometry could provide a 
sensitive approach to assess the GFP expression in a larger population of transfected Blastocystis 
cells. Forward and side scatter signals were used to limit the analysis to viable cells. GFP 
fluorescence signal from mock transfected culture was set as the background so that expression 
levels over the background could be measured. 
Figure 23 shows representative histograms of flow cytometry data. According to the figure, no 
difference in the expression percentage was observed between mock transfected and positive 
control (Figure 23a and b).  
As shown in Figure 23c and d, 3 days after transfection, only 1.35% and 2.07% of cells 
transfected with 200μg of plasmid pcDNA3-ACT pmr-GFP and pcDNA3-GAPD pmr-GFP 
respectively, were found to be expressing GFP. Thereby the data suggested that the vectors with 
putative promoters of selected housekeeping genes of Blastocystis were unlikely to be efficient 







Figure 23. Flow cytometric analysis of GFP expression. X-axis displays the intensity of the 
detected signal increase compared to background (mock) and the Y-axis measures the number of 
events (cells) counted. Expression efficiencies (%) in population of electroporated Blastocystis 






4 CHAPTER 4: DISCUSSION 
 
EV71 is a major causative agent of HFMD, and currently there are no effective medications and 
prophylactic vaccine against HFMD. Taking the socioeconomic impacts of the disease into 
account, it is essential to develop an efficacious vaccine for HFMD.  
Numerous EV71 vaccine candidates including chemically-inactivated, synthetic peptides, 
recombinant subunit, virus-like particles and DNA vaccine were developed and reported in 
literature (Chou et al. 2012); however, these vaccine candidates have their own specific 
limitations among which providing broad immunogenicity and protection against EV71 infection 
are the major drawbacks (Li et al. 2014). Thus, there is still compelling need for future studies to 
further develop safe and improved vaccine candidates against EV71 infection with ability to 
trigger satisfactory levels of immunogenicity and protection against EV71 infection. 
It is believed that recombinant subunit vaccines are safe and cost-effective. Recombinant VP1 
(rVP1) antigen produced and purified from various expression systems was previously reported 
in several studies that could elicit strong EV71 virus neutralizing antibody responses in mice. 
However they are less immunogenic than inactivated whole-virus vaccines (Lee & Chang 2010). 
The low immunogenicity problem of recombinant subunit vaccines could be solved by giving 
repeated vaccination (for proper life-long immunity) and use of effective adjuvants (Perrie et al. 
2008). 
Expression strategies for production of the candidate antigen closest to its natural antigenic 
structure is an essential factor that impacts on the success of a vaccine candidate.  
In this study, CHO and Blastocystis sp. were selected to investigate their feasibility to be applied 
as expression hosts for development of new vaccine candidates against EV71.  
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There is considerable knowledge about CHO-based expression system. However, its application 
has not been reported in EV71 VP1 expression for vaccine end-use. Previously, CHO has been 
shown to be successful for production of hepatitis B subunit vaccine (Zhang, Ma et al. 2011; 
Wang, Ma et al. 2015). This led us to choose CHO as the potential expression system for 
production and purification of VP1 antigen of EV71.   
In addition, Blastocystis, a gut protozoan, was also considered to be tested as expression system 
for EV71 VP1. The hypothesis is based on the fact that Blastocystis naturally colonizes the 
human gut; therefore it could be an attractive eukaryotic host for heterologous protein expression 
and delivery in the digestive tract in order to induce the gut mucosal immunity against EV71 
whose route of transmission is oral-fecal.   
The important point to note here is the pathogenicity issue of Blastocystis in human which raises 
a major concern for its application as a live vaccine in children. Although this pathogenicity is 
controversial, it can be allayed with using a Blastocystis-based vaccine prepared from a non-
pathogenic strain of Blastocystis. 
There is a lack of publication on using Blastocystis as expression system. Thereby, there are 
many unknowns about genetic information, transfection and expression systems in Blastocystis.   
We employed a simplified vector design strategy to express GFP gene in Blastocystis by cloning 
around 1kbp region upstream of the start codon (as putative promoter region) of two native 
housekeeping genes of Blastocystis, namely β-actin (ACTB) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPD), into the parental mammalian expression vector pcDNA3.1/CT-GFP. 
These putative promoter regions were presumed to drive the GFP expression in Blastocystis sp. 
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In this project, heterologous gene expression (GFP, VP1, GFP-VP1) was attempted in CHO and 
Blastocystis sp. cells. In the continuation, the findings, encountered challenges, limitations and 
possibilities are discussed.    
 
 
4.1 EV71 VP1 expression in CHO cells 
 
Reporters of expression can offer a facile and instant means to monitor protein expression in vivo 
(Dalton & Barton 2014). One such widely used reporter protein in cell biology research is Green 
Fluorescent Protein (GFP). GFP is a 27 kDa, intrinsically fluorescent and non-toxic protein that 
was first isolated from the jellyfish Aequorea victoria. A great advantage of GFP is that it 
fluoresces when exposed to UV or blue light without need for any substrate (Deo & Daunert 
2001).  
Some labs have demonstrated the successful use of GFP as a reporter for prediction of gene 
expression in transient expression experiments, enabling researchers to directly visualize and 
localize GFP-tagged proteins within living cells with most conventional epifluorescence and 
confocal filter sets (Chaudhary et al. 2011). 
In this study, successful transfections of the pcDNA3.1/CT-GFP control expression plasmid was 
shown by bright GFP flourescence under the fluorescent microscope. However, fluorescence of 
GFP was markedly reduced following transfection of CHO cells with constructed GFP-tagged 
VP1 plasmid. It is likely that the fusion proteins are expressed but the final tertiary structure of 
the fusion proteins have interfered with GFP folding and therefore resulted in low GFP 
fluorescence. To address this, further analysis by western blot was performed and showed no 
detectable rVP1 expression in either lysates or supernatants of transfected CHO cells. 
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It was questionable whether GFP and the inserts were in frame. In response to this question, in-
frame integration of VP1 before GFP was rechecked and reconfirmed by sequencing. 
Perhaps, GFP-tag fused to the carboxyl-terminus of VP1 could have a dramatic effect on overall 
expression in CHO cells. Similar issue was reported by some researchers due to the fact that 
tagging a protein with GFP, which is relatively large (27 kDa) might adversely affect the protein 
expression (Palmer & Freeman 2004). 
Since GFP appeared to interfere with expression of VP1, another pcDNA3 vector was sought. 
pcDNA3.1/myc-His was used for expression of rVP1 as a His-tagged protein for subsequent 
purification by Immobilized Metal Affinity Chromatography (IMAC). 
C-terminal myc and poly-His tags adds approximately 3 kDa to the size of the protein of interest. 
This is significantly smaller than GFP tag and is less likely to affect the tertiary structure and 
biological activity of the fusion protein (Terpe 2003). Another advantage is the availability of 
anti-Myc and anti-His antibodies for western blot analysis of rVP1-Myc/-His expression. 
VP1 fused to dual tags, myc and His, was successfully expressed in CHO cells and confirmed by 
three antibodies, namely anti- EV71 VP1, anti-myc and anti-His at the same size. This construct 
can be used for subsequent production of rVP1 in CHO and further purification for vaccine end-
use. 
 For high-level protein production and convenient single-step purification from mammalian cells, 
secretion is preferable to cytoplasmic production. A common strategy to enhance the 
extracellular production of a desired protein in CHO cells is to fuse it with a suitable signal 
peptide (Florin et al. 2009).  
Given that adiponectin is a secreted protein whose signal peptide is well established (Dalamaga, 
Diakopoulos et al. 2012), we predicted the CHO adiponectin signal peptide and its coding 
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nucleotide sequence was fused to VP1 gene via overlap PCR; the fused fragment (ADPQSP-
VP1) was cloned into both expression vectors pcDNA3.1/CT-GFP and pcDNA3-myc/His 
assuming to direct the secretion of VP1 to the growth medium of CHO.  
Western blot analyses to detect GFP tagged SP-VP1 in culture supernatants remained 
unspecified due to cross-reactivity between antibodies and serum which obscured the expected 
region of secreted fusion protein.  
While western blot analyses could detect myc/His tagged ADPQSP-VP1 in the cell lysates of 
transfected CHO cells, none was detected in the culture supernatant of transfected CHO cells 
suggesting that the signal peptide failed to be functional. This could be due to a variety of 
possible reasons including impaired release of fusion protein from the secretary pathway of CHO 
cells as a result of improper protein conformation (Peng et al. 2011), low level of protein 
expression, and poor stability of secreted protein in the cell culture. 
We tried concentrating the culture supernatant to increase the chance of detection of the 
expressed rVP1 protein but enhanced the bovine albumin cross-reactivity with the antibody 
which obscured the identity of the bands. Overcoming this issue may be achieved by further 
experiments as follows: 
(1) To use CHO specific commercially available serum-free media. Cultivation of transfected 
cells in serum free medium is preferable for characterization of secreted recombinant proteins 
(Dalton & Barton 2014) ; (2) To carry out pull-down assay (immunoprecipitation) to trap and 
isolate GFP- or Myc- tagged VP1 or Bovine albumin from the macromolecular complexes using 
Protein A/G beads; (3) To employ improved secretion engineering strategies in CHO cells in 
order to increase VP1 production yield.  
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The use of mammalian cell hosts for production of biopharmaceutical protein is growing in 
popularity among academic laboratories (Dalton & Barton 2014). This is because mammalian 
cell hosts are more likely than lower eukaryotic and bacterial cell hosts to express, properly fold, 
and result in native-like post-translational modifications/processing of recombinant proteins for 
use in immunization or many other applications (Scholz et al. 2013). CHO cells are widely used 
amongst mammalian cell hosts for production of recombinant protein in biopharmaceutical 
market for the reasons discussed in the introduction chapter (section 1.5.1).  
In this project, the expression of multiple VP1 fusion expression constructs were tested, and 
eventually one construct (pcDNA3-VP1-myc/His) could successfully express EV71 VP1 in CHO 
cells intracellularly. However, despite selection of transfected CHO cells under G418 pressure, 
the VP1 protein production yield was found to be somewhat low.    
The expression levels in mammalian cells are typically lower as compared to bacterial systems 
and often only small amounts of mammalian cell material is available. Another difficulty is the 
scarcity of detailed practical protocols which are restricted to pharmaceutical industry due to 
trade secrecy (Dalton & Barton 2014). Thus, production of recombinant protein using 
mammalian expression systems even though on the milligram scale seems a challenging and 
slow task in academic labs.  
Over-expression experiments including creation of stable expression, use of signal sequences for 
secretion in the medium, media formulations, and methods for large-scale growth can be tried to 
enhance the VP1 production in CHO cells.  
We exploited transient expression in CHO as a rapid route to obtain rVP1 protein. However, it 
needed large amount of transfection reagents and plasmid DNA which was costly. Furthermore, 
it yielded relatively low rVP1 protein production. By contrast, creation of stable CHO cells can 
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be performed to provide a consistent and reliable high-level protein production. Stable CHO cell 
line can be stored under cryogenic conditions for long term, retrieved, and cultured for 
purification of VP1 (Kingston et al. 2002). However, the establishment of CHO cells that stably 
produce high amount of recombinant protein is time-consuming (takes months) and labor-
intensive; notably there is potential loss of expression with passage. (Kim, Kim et al. 2012).  
 
 
4.2 Heterologous gene expression in Blastocystis sp. 
 
There are numerous challenges and unknowns associated with developing heterologous gene 
expression systems in Blastocystis. Up until now, there has been lack of publication on 
genetically manipulating Blastocystis due to limited information about its genetic (gene 
organization, gene expression, etc.). In addition, no working transfection protocol has been 
reported. Thus, its use for heterologous expression systems is a challenging and risky project. 
However, this project took the courage to investigate the transfection methodology for 
heterologous protein expression in Blastocystis. 
The first challenge faced was lack of any previous report on experimentally validated promoters 
for Blastocystis. The available Blastocystis genome database was not informative in relation to 
promoter annotations. To tackle this, our strategy was to clone approximately 1kb sequence 
derived from 5’ upstream the start codon of two Blastocystis native housekeeping genes, namely 
β-actin (ACTB) and Glyceraldehyde 3-phosphate dehydrogenase (GAPD), into mammalian 
expression vector pcDNA3.1/CT-GFP upstream of the GFP gene. These putative Blastocystis-
derived promoters were presumed to drive the expression of GFP in Blastocystis. 
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Considering the lack of previous reported transfection method for Blastocystis, we tried 
conventional electroporation for transfection of Blastocystis based upon protocols reported for 
other protozoa including Giardia lamblia (Davis-Hayman & Nash 2002), Trypanosoma cruzi 
(DaRocha, Silva et al. 2004), Entamoeba histolytica (Nickel & Tannich 1994) and Toxoplasma 
gondii (Zhang, Zhang et al. 2013). However, we found no growth in transfected Blastocystis 
culture. We then carried out many rounds of trial-and-error electroporation optimizations for 
Blastocystis.  
Since Blastocystis is an anaerobic protozoan, the process of electroporation itself could be 
detrimental to Blastocystis cell viability. To tackle this problem, the process was performed as 
rapid as possible to minimize the exposure to atmospheric oxygen. The electroporation 
conditions which resulted in higher Blastocystis cell viability observed by cell pellet growing in 
routine culture tubes were optimized. However, the efficiency of this optimized electroporation 
protocol with regard to plasmid DNA take up by Blastocystis cells remained unanswered due to 
lack of a DNA plasmid delivery control.  
In order to address whether plasmid DNA could gain entry into Blastocystis cells after the 
employed optimized electroporation method, plasmid delivery control strategy will be helpful. 
The optimizations of plasmid DNA delivery in cells can be achieved by using fluorescent-
labeled plasmid DNA. The DNA plasmids which are purified using maxi prep kits can be 
fluorescein-labeled by the utilization of Label IT
®
 Tracker Intracellular Nucleic Acid 
Localization Kit (Mirus, USA) to prepare plasmid delivery controls. The DNA plasmid can be 
incubated with the reagent as per instruction of the manufacturer. Then it can be separated from 
the dye through chromatography columns  (Morachis et al. 2012). The plasmid delivery controls 
will facilitate the visualization of plasmid DNA uptake by Blastocystis cells via confocal 
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microscopy after a transfection experiment. Furthermore, a quantitative approach by flow 
cytometry analysis will help us determine the efficiency of the transfection method in relation to 
the amount of plasmid DNA uptake and cell viability. Thus, we would be able to compare the 
effect of various transfection methods on Blastocystis in order to characterize the protocol which 
leads to maximal plasmid DNA uptake and minimal cytotoxicity.  
Of note is that, Blastocystis cells are surrounded by glycosylated surface coat (Cassidy et al. 
1994) which may serve as a potential barrier to render Blastocystis cells refractory to be 
transfected, and perhaps Blastocystis could be categorized as a hard to transfect organism.  
 It seems that enzymatic and/or chemical treatments could disintegrate the surface coat of 
Blastocystis. The effect of such treatments on the plasmid DNA uptake and cell viability of 
Blastocystis could be assessed by the above mentioned plasmid delivery control strategy. 
GFP expression in Blastocystis cells was photographed under confocal microscope; the results 
revealed no visually distinguishable difference between mock-transfected and transfected 
Blastocystis cells. On the other hand, we observed noticeably high auto-fluorescence level in 
Blastocystis after electroporation experiments. Increased levels of auto-fluorescence is likely due 
to dying or sick cells (Hennings et al. 2009; Dittmar et al. 2012). This may create confusion with 
the use of GFP fluorescence and may result in misleading conclusions in experiments. When the 
auto-fluorescence was suppressed to its minimum based on mock-transfected cultures, GFP 
fluorescence was unfortunately rather dim. Indeed, dim GFP florescence due to low efficiency of 
transfection is known to be a limiting factor for acquiring conclusive data, especially in difficult 
to transfect cells (Ducrest et al. 2002). 
Taking into account the Blastocystis cell morphology, GFP fluorescence is expected to be 
distributed in periphery rim of Blastocystis cells because the thin cytoplasm surrounds a central 
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vacuole. Therefore, it is predicted to be a hard task to distinguish between real GFP fluorescence 
and auto-fluorescence by eye under confocal microscopy, especially in case of low expression 
level of GFP.  
Likewise, flow cytometry analysis showed low GFP expression efficiency (less than 5%) 
following transfection of Blastocystis with constructs carrying the putative promoter sequences 
derived from the β-actin and GAPDH native housekeeping genes of Blastocystis.   
One challenge in working with Blastocystis was that it grew as suspension and we found no 
feasible way to separate dead cells from viable cells. This separation is essentially important for 
two purposes: (1) Including the dead cells after electroporation would probably result in the 
observed high auto-florescence during confocal microscopy analyses; (2) To establish the effect 
of antibiotic G418 selection on the transfected Blastocystis culture. The culture suspension was a 
mix of live and dead cells. Both live and dead cells were similar in shape under microscope. This 
problem remained unanswered in our project. In contrast, in CHO cells, while dead cells easily 
rounded up and detached from the flask surface during antibiotic G418 selection, live cells 
remained attached. Live / dead cell sorting based on distinct biomarkers and/or understanding the 
distinct physical differences between dead and live Blastocystis cells will probably facilitate their 
separation.  
Apart from transfection efficiency of our electroporation strategy, other factors including 
ineffectiveness of putative promoters for driving the expression of GFP, and incompatibility of 
pcDNA3 mammalian expression vector with Blastocystis expression system might be the likely 
reasons for very low level of GFP expression observed after transfection of Blastocystis. 
Since the efficiency of heterologous protein expression in host systems can be diminished by 
biased codon usage (Burgess-Brown et al. 2008), codon optimization is normally considered to 
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enhance the expression levels in prokaryotic and eukaryotic expression systems (Yadava & 
Ockenhouse 2003). For expression of GFP / VP1 in Blastocystis, their codon-optimized gene can 
be designed based on the codon bias of Blastocystis using a free software (Fuglsang 2003). 
Noteworthy is the flow cytometry data derived from multiple independent experiments 
consistently showed that the construct containing the putative promoter region of GAPDH 
housekeeping gene of Blastocystis yielded almost two times higher expression level compared to 
β-actin. This warrants its further investigation to assess its suitability in driving the heterologous 
gene expression in Blastocystis.  
It seems prudent to explore the expression efficiency by using multiple vector-series in parallel. 
Some candidate expression vectors can be investigated including those reported to work 
successfully in other protozoa such as circular (supercoiled) pMD18-T in Toxoplasma gondii 
(Zhang, Zhang et al. 2013); linearized and circular (supercoiled) pGEM-T in Perkinsus 
(Fernandez-Robledo et al. 2008) and in Giardia lamblia (Davis-Hayman & Nash 2002); 
linearized pPICZ in Pichia pastoris (Wang, Jiang et al. 2013). It is likely that yeast-based 
expression vectors work more efficiently than mammalian-based vectors in Blastocystis. 
The presence of a reporter gene in expression plasmid vector is essential as a marker for visual 
inspection as well as for quantification of gene expression in cells (Stretton et al. 1998).  
Characterizing a suitable reporter system for Blastocystis is sorely needed in order to acquire 
conclusive data during reporter assays involved in heterologous gene expression evaluation. 
Plasmid vectors containing the luciferase reporter gene were reported to be better for optimizing 
the overall transfection efficiency. By contrast, plasmid vector containing the GFP reporter gene 
can help determine the actual number of transfected cells using already stablished protocol 
(DaRocha, Silva et al. 2004).  
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Many researchers who used Green Fluorescent Protein (GFP) for biological investigations have 
reported the cellular auto-fluorescence, otherwise known as endogenous auto-fluorescence, as a 
common nuisance. When using GFP reporter in Blastocystis, we encountered difficulties 
including low contrast and clarity in green fluorescence and high auto-fluorescence which led to 
low signal-to-noise ratios in confocal microscope images. Hence, distinguishing GFP from auto-
fluorescence remained confused.  
The Green Fluorescent Protein (GFP) hybrid with the protein of interest is a powerful reporter to 
track gene expression in cells. However, since GFP relied on oxygen for chromophore 
maturation to achieve maximum fluorescence, its visualization, unless highly expressed, is 
inherently difficult in anaerobic cells (Sateriale et al. 2013). Recently, an alternative to GFP, 
derived from RFP, called mCherry was potentially useful experimentally to exhibit brighter red 
fluorescence with N-terminal fusion proteins in anaerobic condition (Fink et al. 2010; Ransom et 
al. 2015). 
GFP is truly a versatile marker for visualizing and distinguishing successful transfection, 
monitoring subcellular protein localization and reporting on gene expression. However, unless 
GFP expression is very high or its localization is dense, its fluorescence signal will not be 
specific enough to adequately discriminate between GFP signal and auto-fluorescence. Auto-
fluorescence arises from disparate endogenous cellular metabolites or molecules in the growth 
media (Billinton & Knight 2001). 
Therefore, based on the above information, to tackle the problem of GFP for reporting on the 
gene expression in Blastocystis, the use of other reporters can be tried. Expression vectors 
containing identical backbone but coding either for luciferase (pGL3) or red fluorescent protein 
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(mCherry) can be transfected into the Blastocystis cells to compare their utility in Blastocystis 
gene expression, in particular for promoter studies.  
Bioinformatics approaches have been used to identify promoters in various organisms’ genomes 
(Rombauts et al. 2003; Roy et al. 2013). Collaboration with experts in bioinformatics will help 
employ robust omics-based approaches and tools to identify strong constitutive promoters in 
Blastocystis genome. Such promoters can be used for construction of specialized well-designed 
expression vectors for Blastocystis. However, the efficacy of these promoters in driving 
heterologous gene expression in Blastocystis ought to be validated experimentally. 
 
 
4.3 Conclusion  
 
In this project, expression of EV71 VP1 antigen was explored in novel expression hosts CHO 
and Blastocystis cells for future novel vaccine candidate development against EV71 infection.  
This study has successfully developed an expression construct that was able to produce VP1-
myc/His fusion protein in CHO cells despite relatively low production yield. Therefore, the 
recombinant VP1 could be further scaled up and used for development of safe CHO-derived VP1 
subunit vaccine against EV71 virus. 
In this project, our attempts within the time limit was unsuccessful in proving the GFP 
expression in Blastocystis due to numerous technical challenges. Being the first heterologous 
gene expression study of Blastocystis, this project has unambiguously contributed to the 
literature by addressing the key hurdles. In future, the suggestive approaches and complementary 
experiments discussed in this project, each could be a mini-project itself, will assist researchers 
in achieving the mystery of heterologous gene expression in Blastocystis.  
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5 CHAPTER 5: FUTURE DIRECTIONS   
 
 
5.1 Purification of recombinant VP1 antigen expressed in CHO cells 
 
After obtaining relatively high amount of CHO-derived VP1 expression following the earlier 
discussed strategies for protein over-expression, subsequent purification via affinity 
chromatography can be considered. Since the produced rVP1 is fused to polyhistidine affinity 
tag, immobilized metal-affinity chromatography (IMAC) (Bornhorst & Falke 2000) can be 
employed for purification. 









) immobilized on a column matrix. After washing the matrix material, rVP1 
containing polyhistidine tag can be easily eluted by addition of free imidazole to the column 
buffer (Porath 1992). Various immobilized metal matrices are available for application in IMAC. 






-CMA) (Bornhorst & Falke 2000) can facilitate the purification of 
polyhistidine tagged rVP1. 
 
 
5.2 Utilization of Amaxa Nucleofector® technology for transfection of Blastocystis 
 
Although electroporation is routinely used for laboratory gene transfection, it is generally 
employed using trial-and-error optimization schemes to check the electroporation's effects on 
cells. Recently the use of Amaxa Nucleofector
®
 technology has been reported successful 
compared to BioRad GenePulser II electroporation system in achieving high efficiency 
transfection in protozoan parasites (Jongco et al. 2006; Fernandez-Robledo, Lin et al. 2008) and 
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difficult to transfect cell lines (Maasho et al. 2004; Flanagan et al. 2012). For example, its 
application for transfection of Babesia bovis has been shown more efficient than electroporation 
for transfecting small quantities of plasmids (Suarez et al. 2007). Therefore, it seems rational to 
carry out some optimization experiments on Blastocystis using Amaxa Nucleofector
®
 
technology, however the operating cost will be significant. 
 
 
5.3 Immunization/Challenge study (Phase III of the project) 
 
After enough purified CHO-derived recombinant VP1 antigen is achieved, the project will move 
to its next phase which is immunization studies in BALB/c mice. For this, mice (5-6 weeks) will 
be immunized intraperitoneally and/or intramuscularly with mix of rVP1 (20 µg) and adjuvants 
at days 0, 7 and 21. Control groups will be injected with PBS and adjuvants only. Blood samples 
will be collected at day 0, 14, and 28 for carrying out EV71 virus neutralization assay on the sera 
to assess the neutralizing antibody against EV71 virus. Measurement of IgM and IgG antibodies 
in sera will be conducted by ELISA. Blood (cardiac puncture) and spleens will be harvested from 
the immunized mice at day 42; subsequently PBMC and splenocytes will be isolated for INF-
gamma ELISPOT assay in order to evaluate the elicited cellular response against the vaccine. 
As a prospective novel adjuvant, Aldara (imiquimod) will be used in immunization regimens for 
further enhancing the immunogenicity. The rationality of choosing this novel adjuvant in 
combination with purified CHO-derived VP1 antigen is provided in the following: 
Toll-like receptors (TLRs) of the innate immune system are known targets for enhancing vaccine 
efficacy (Zhang et al. 2014). TLR7 activation induces inflammatory cytokine expression and 
maturation of antigen presenting cells (Mohty et al. 2003). Imiquimod is a synthetic TLR7 
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agonist represented as a new class of adjuvants. Imiquimod is the active ingredient in a topical 
cream called Aldara, which has been approved by the FDA for the topical treatment of genital 
warts caused by human papilloma viruses. Moreover, imiquimod was reported to expedite the 
immune response against influenza virus infection when combined with influenza vaccine 
(Zhang, Li et al. 2014). Furthermore, imiquimod has been utilized as an immunomodulator in 
cutaneous leishmaniasis therapy and has been shown to induce the release of a number of 
cytokines, including interferon gamma (IFNγ), tumor necrosis factor (TNF)-α, interleukin (IL)-
1b, IL-6, and IL-8 (Zhang & Matlashewski 2008). Preclinical and clinical data demonstrate that 
imiquimod will lead to local activation of antigen presenting cells that can subsequently enhance 
T cell priming (Mahto et al. 2010).  
Once substantial immune response against the EV71 is achieved by in vitro evidence 
(ELISA/Neutralization assay), challenge studies in AG129 mice will be performed to evaluate 
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Appendix 1: Map of mammalian expression vector pcDNA3.1/CT-GFP  
 
 
Figure 24. Vector map of the pcDNA3.1/CT-GFP TOPO vector. The GFP is linked to the 5’ end 
of the PCR insert encoding for green fluorescent protein serving as a reporter molecule.  
Ampicillin and neomycin-resistance markers are present in the vector to enable recombinant 
selection. High-level expression of the insert is under the control of strong cytomegalovirus 
(CMV) promoter. Position of a PCR insert with 5’-adenine (A) overhang and TOPO isomerase I 









Figure 25. Vector map of pcDNA3.1/myc-His A. The vector contains strong cytomegalovirus 
(CMV) promoter for high-level expression in mammalian cells, two selection markers, dual 
epitope tags (myc and 6×His) for easy detection with anti-epitopes monoclonal antibodies and 








Appendix 3: Solutions for preparing 12% resolving gel and 4% stacking gel for SDS-PAGE 
 
Component Volumes for 2 gels (ml) 
12% Resolving Gel 4% Stacking Gel 
Milli Q H2O 3.4 3.05 
30% Acrylamide Mix 4 0.85 
Resolving Gel Buffer (1.5 M 
Tris pH 8.8) 
2.5 - 
Stacking Gel Buffer (0.5 M Tris 
pH 6.8) 
- 1.25 
10% SDS 0.1 0.05 
10% APS 0.05 0.05 
TEMED 0.015 0.015 
 
 
